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ABSTRACT 
 
Background 
Diabetes is a global epidemic. The International Diabetes Federation estimates that there 
are at least 285 million diabetics worldwide and this is estimated to grow to over 440 
million by 2030
 1 
. A study was conducted at the Helen Joseph Hospital Diabetic clinic in 
an attempt to identify predictors of glycaemic control and to compare the level of care to 
the 2012 Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) 
guidelines. 
 
Methods 
Patients were recruited from the Helen Joseph Hospital Diabetic clinic. To be included the 
patient had to be part of the coloured (mixed race) community, be willing to give informed 
consent, be older than 18 years, have an HBA1C taken within 6 months, have a diagnosis of 
Type 2 diabetes mellitus and be a clinic attendee for at least 1 year.  Pregnant patients, 
Type 1 diabetic patients, patients with a psychotic disorder or aphasia were excluded.  Data 
collection consisted of face-to-face interviews, review of treatment, medication knowledge 
evaluation, a short examination and collection of recent blood results. Statistical analysis 
was done by stratifying patients into two groups by using the mean HBA1C. Variables with 
a p < 0.1 from this analysis were used in a logistic regression model. In addition, the 
correlation between continuous variables were tested. A comparison was made between the 
level of care and the 2012 SEMDSA guidelines. 
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Results 
A total of 100 patients were recruited into the study. The mean age was 62.8 years with 
mean duration of diabetes of 15.8 and clinic attendance of 10.9 years. The group had very 
poor education level and the median income of R1200 per month was also low. The mean 
HBA1C was found to be 9.74%, well above the target recommended by SEMDSA. 
Knowledge of diabetes with respect to management and complications was very poor. 
Age > 50 years (OR 0.372 CI 0.06-2.26), estimated glomerular filtration rate ≥ 60 
ml/min/1.73m
2
 (OR 0.90 CI 0.25-3.27), experiencing a microvascular complication (OR 
0.73 CI 0.11-5.07) or any other diabetic complication (OR 0.56 CI 0.07-4.38) and having 
experienced a hypoglycaemic episode (OR 0.31 CI 0.09-1.10) predicted better glycaemic 
control. Duration of diabetes < 10 years (OR 1.36 CI 0.37-5.02), diastolic blood pressure ≥ 
70 mmHg (OR 2.80 CI 0.80-9.78), aspirin dosage ≥ 150 mg daily (OR 6.47 CI 1.60-26.05), 
simvastatin dosage = 40 mg daily (OR 2.35 CI 0.31-18.10) and body mass index > 25 
kg/m
2
 (OR 1.09 CI 0.49-2.41) all predicted a poorer glycaemic result. 
 
HBA1C was found to positively correlate with diastolic blood pressure (p = 0.0024, r = 
0.31). Systolic blood pressure positively correlated with diastolic blood pressure (p < 
0.0001, r = 0.56).  Apart from correlating with systolic blood pressure and HBA1C, diastolic 
blood pressure also positively correlated with the triglyceride level (p = 0.0003, r = 0.36). 
Positive correlations between total cholesterol, triglycerides, HDL-C and LDL-C were 
found. As expected, body mass index and waist circumference correlated positively (p < 
0.0001, r = 0.82).  
 
Level of care was not at the level recommended by the 2012 SEMDSA guidelines. Only 
6% of patients met the waist circumference goal. Only 15% of patients achieved blood 
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pressure goal. Most of the patients (86%) who qualified for aspirin did not receive it. In the 
group of patients receiving aspirin 33% did not qualify. According to the SEMDSA 
guidelines, most of the patients not receiving a statin (90%) should have been on statin 
therapy. Only 23.5% of patients on statins were at lipid goal. The frequency of laboratory 
testing did not meet SEMDSA guidelines. There were 31 (31%) patients without a urea, 
creatinine and electrolyte test for the previous year and 37 (37%) patients without a 
lipogram for the previous year. Only 21 patients had a listed urine albumin/creatinine ratio 
and only 33% of these had been done in the previous year. 
     
Conclusions 
Various new variables were identified in the search for predictors of glycaemic control. It 
was surprising to find that education level, monthly income, smoking status and knowledge 
of diabetes did not have a statistical impact on glycaemic control. Increased age, duration of 
diabetes, glomerular filtration rate, hypoglycaemic frequency and diabetic complications 
experienced were associated with improved glycaemic control. Increased diastolic blood 
pressure, aspirin dosage, statin dosage and body mass index were associated with worse 
glycaemic control. The standard of care in the clinic was found on the whole to be inferior 
to the level of care recommended by SEMDSA. 
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1. CHAPTER 1 – LITERATURE REVIEW 
1.0. Introduction 
Diabetes mellitus is a global epidemic. The International Diabetes Federation estimates 
that there are currently 285 million diabetics worldwide and this is estimated to grow to 
over 440 million by 2030
 1 
. 
 
The global phenomenon of increased diabetes prevalence is also seen in South Africa. 
Helen Joseph Hospital is a tertiary hospital with 700 beds. During 2011 a total of 2808 
patients were seen at the hospital’s diabetes clinic, an mean of 234 patients per month. 
The diabetic clinic serves a specific cohort of diabetic patients being limited to patients 
with Type 1 and certain patients with Type 2 diabetes. The Type 2 diabetes patients are 
only accepted from other clinics if they are on insulin and not achieving adequate 
glycaemic control i.e. controlling blood sugar within certain targets. This population of 
patients seen at the diabetic clinic thus excludes the diabetic population attending the 
other clinics at the hospital and also those undiagnosed. In the United States it is 
estimated that one third of patients are not aware they are suffering from diabetes
 2 
.  
 
The economic cost of management of the disease is enormous and the long-term 
complications, both macro- and microvascular, are devastating. Macrovascular 
complications include stroke, ischaemic heart disease and peripheral vascular disease. 
Microvascular complications include diabetic nephropathy, diabetic retinopathy and 
diabetic neuropathy. Numerous studies have shown that improved glycaemic control can 
delay or even prevent the development of both micro- and macrovascular complications
 3 
. 
However, tight glycaemic control is often difficult to achieve.  
 2 
 
 
Limited data has been published on predictors of glycaemic control. Currently there is no 
published South African data. The main aim of this study was to attempt to find factors 
predicting glycaemic control in the diabetic clinic population at Helen Joseph Hospital. A 
secondary aim was to correlate HBA1C, blood pressure, lipids, body mass index and waist 
circumference and to assess the standard of care in the clinic with respect to the 2012 
Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) 
guidelines for management of Type 2 diabetes.  
 
In the following sections risk factors for predicting glycaemic control as found in the 
literature will be discussed. There will also be a brief focus on controlling blood pressure 
and dyslipidaemia as these are also important in securing the health of the diabetic 
patient. This will be followed by a critical review on current literature on guideline 
adherence with focus on the South African context. 
1.1. Factors found in literature to predict glycaemic control 
1.1.1. Factors worsening glycaemic control 
Various factors in the literature have been cited as worsening control. Smoking, 
which increases insulin resistance and exacerbates the risk of cardiovascular 
disease in diabetics, long working hours and false perceptions of control and 
treatment in the Spanish speaking population of Northeast Colorado have all been 
cited
 18 , 64 , 65 
.  
 
Caffeine ingestion worsens control, especially when taken postprandially. This is in 
contrast to the protective effect of caffeine for developing diabetes, but only a few 
 3 
 
small studies have been done
 43 
. The ingestion of soda drinks may also worsen 
control
 66 
.  
 
Depressive symptoms worsen HbA1c values in Type 1 diabetics but not Type 2 
diabetics. However adherence to diet and exercise falls in both groups when 
depressive symptoms are present
 67 
.  
1.1.2. Factors improving glycaemic control 
Various factors have been researched and found to improve glucose control.  
Weight loss has been suggested
 11 
. Some authors argue that as little as 5% weight 
loss can improve glucose control
 68 
. Weight loss ironically, is also a beacon of poor 
control as it is one of the symptoms of diabetes
 69 
.  
 
In addition, physical activity also improves glucose control. Most studies 
recommend at least 150 minutes of moderate exercise per week
 68 
. It seems that 
patient support groups can play a positive role in enforcing physical activity
 70 
. A 
higher level of education is a strong predictor of increased activity if the patient has 
available time
 71 
. The intensity of the exercise does not seem to play a role when 
the same amount of calories are burned
 72 
.  
 
Lifestyle modification and continuous lifestyle intervention programmes have been 
shown to improve control
 14,73 , 74 
. Lifestyle modification seems to be effective in 
the management of diabetes irrespective of family history
 75 
.  
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Diabetes education has been positively linked with good control. In a study among 
Turkish immigrant diabetic patients poor compliance indicators included duration 
of diabetes and poorer knowledge of diabetes
 76 
.  
 
Age, motivation and an increase in diabetes knowledge level were all cited in one 
article as improving control
 77 
. Pharmacological therapy was also shown to be of 
benefit
 68 
.  
 
Proper nutrition, consisting of a low-fat reduced calorie diet has been suggested as 
improving glucose control
 68 , 78 
.  
 
Self-monitoring of blood glucose in Type 2 diabetes, home monitoring by a public 
health nurse and follow-up phone call interventions have all been shown to be of 
benefit
 79 - 80 
. 
 
A moderate amount of alcohol ingestion, visual display of HbA1c values with target 
values, providing primary care physicians with an electronic system guiding 
decision-making with respect to diabetic control and learned resourcefulness all 
played positive roles in glucose control
 66  81 - 82 
. 
 
Physician attitude at the time of diagnosis strongly influences the patient’s 
perception of the seriousness of the disease, and this can have a positive effect on 
their control
 83 
.  
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1.2. Factors influencing blood pressure and lipid control 
As far as control in diabetic patients is concerned, glucose control is not the only target.   
Hypertension, dyslipidaemia and microalbuminuria must also be targeted
 78 
.  
 
Hypertension increases the risk of both macro- and microvascular complications in 
diabetes
 84 
. The latest Society for Endocrinology, Metabolism and Diabetes of South 
Africa (SEMDSA) guidelines published in 2012, support a target blood pressure between 
140/80 and 120/70 mmHg based on the latest data available
 84 
. In patients with primary 
or essential hypertension pharmacological intervention and lifestyle modification play a 
role. The 7th report of the Joint National Committee on prevention, detection, evaluation, 
and treatment of high blood pressure (JNC7), which will be updated by the JNC8 later 
this year, lists the following lifestyle factors as being beneficial in the management of 
hypertension: weight loss in overweight patients, following the Dietary Approaches to 
Stop Hypertension (DASH) plan, a reduction in dietary sodium, regular aerobic physical 
activity and limitation of alcohol intake
 85 
.  
 
Dyslipidaemia also plays a major role in the macrovascular complications of diabetes and 
is a major risk factor for the development of atherosclerosis
 86 
. There is strong evidence 
supporting the notion that reducing total cholesterol (TC) and low density lipoprotein 
cholesterol (LDL-C) reduces the risk of cardiovascular disease
 87 
. Type 2 diabetes is 
considered a coronary artery disease risk equivalent by some authors implying that 
dyslipidaemia should be treated aggressively in this cohort of patients
 86 
.  
 
Apart from pharmacological intervention in managing dyslipidaemia, lifestyle 
intervention should always be encouraged. The strongest driving dietary factor is dietary 
 6 
 
saturated fatty acids. Dietary trans-fat, also called unsaturated fat, increases LDL-C
 87 
. In 
contrast, increased dietary fibre intake reduces serum cholesterol
 87 
. Weight loss is 
beneficial but the effect is small, with only a 0.2 mmol/l drop in LDL-C for every 10kg of 
weight lost
 87 
. The effect of exercise on LDL-C is even smaller and less than the effect 
achieved by weight loss
 87 
.  
 
Triglyceride levels are lowered by a reduction of excessive body weight, reduction in 
alcohol use and in the intake of carbohydrates (mono- and disaccharides) and an increase 
in physical activity and ingestion of n-3 polyunsaturated fat which can be found in fish
 87 
.  
 
High density lipoprotein (HDL) is thought to be protective against cardiovascular disease. 
A reduction in dietary trans-fat, an increase in physical activity, a reduction of excessive 
body weight, a reduction in dietary carbohydrates, and when utilizing carbohydrates, 
choosing ones with a low glycaemic index and high fibre content, all increase HDL 
levels. Alcohol should also be used in moderation and smoking should be discouraged
 87 
.  
 
1.3. Diabetes guideline adherence with focus on the South African experience 
The Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) 
publishes guidelines every three to 4 years on the management of type 2 diabetes 
mellitus. The most recent guidelines were published in 2012. 
 
Guidelines are the best practice available in managing patients based on the latest 
published literature. Guideline adherence improves outcome. In 2004, Distiller published 
data confirming that guideline adherence is possible and showed that patients did benefit
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88
 . He showed an impressive 90% reduction in hospital admissions of diabetic patients 
after implementation of strict guideline adherence
 88
 . 
 
Adherence to guidelines worldwide is poor. The Centre of Disease control found that less 
than 5% of diabetes patients in the United States received care comparable to that 
prescribed by the American Diabetes Association guidelines
 89
 . 
 
Some work has been done with respect to guideline adherence in South Africa. Just 
recently, while this study was ongoing, Okoroma, Harbor and Ross published a paper 
concluding that there was poor compliance with guidelines at a Kwazulu-Natal hospital
 90
 
. Their comparison was made to the 2009 SEMDSA guidelines. Eighty three percent of 
patients had poor HbA1C’s, lipid tests were rarely performed and foot exams were done in 
only 6% of the patients. 
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2. CHAPTER 2 – MATERIALS AND METHODS 
2.0. Study objective 
Limited literature is available on predictors of glycaemic control in the diabetic 
population and as far as I am aware there is no published South African data on this topic.  
The main aim of this study was an attempt to find predictors of glycaemic control in a 
cohort of diabetic patients attending the Helen Joseph Hospital diabetic clinic. 
 
The main objectives of the study were: 
1. To describe the diabetic population at Helen Joseph Hospital diabetic clinic 
included in the sample with respect to demographics, glucose, blood pressure and 
lipid control as well as knowledge and perception of diabetes. 
2. To compare diabetic patients below the mean HbA1C found in this study to those 
above the mean in order to find factors that may predict glycaemic control.  
3. To correlate HbA1C with blood pressure, lipids, body mass index and waist 
circumference. 
4. To compare the level of care at the clinic to the recommendations of the 2012 
SEMDSA guidelines. 
2.1. Methods 
2.1.1. Data source 
This was an observational, cross sectional study. One hundred patients were 
recruited from the Helen Joseph Hospital diabetic clinic. The sample size was 
calculated using the statistical package Epi Info using a 2-sided confidence interval 
of 95%, a power of 80%, a ratio of unexposed to exposed (factors predicting good 
 9 
 
control) of 4:1, percentage of unexposed with outcome 10% and percentage of 
exposed with outcome 50%. With these parameters the software calculated a 
required sample size of 67. As sample size can merely be predicted using statistical 
mathematics, the decision was taken to increase the sample size to 100 patients in 
an attempt to ensure statistical significance at the end of the study. 
 
To be included in the study the patients had to satisfy the following criteria: be part 
of the coloured (mixed race) community, be able and willing to give informed 
consent, be older than 18 years, have an HbA1C taken within 6 months of the 
interview date, have a diagnosis of Type 2 diabetes for at least 1 year and have 
been followed up at Helen Joseph Hospital diabetes clinic for at least 1 year. This 
study focused on this population group in an attempt to reduce cultural bias. The 
coloured community is the largest population group attending the clinic. This 
would potentially facilitate patient recruitment. 
 
Patients who were pregnant, known to have Type 1 diabetes, have a known 
psychotic disorder or who had suffered a stroke and subsequent aphasia were 
excluded from the study. 
 
Ethics approval was obtained from the Human Research Ethics Committee 
(Medical) of the University of the Witwatersrand, Clearance Certificate No 
M120844 (Appendix A). 
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2.1.2. Data collection 
Data was collected at the Helen Joseph Hospital diabetic clinic. The clinic is open 
to patients every Wednesday, except for public holidays. On selected Wednesdays 
the clinic is open to Type 1 diabetic patients only. These clinic days were not used 
to recruit Type 2 diabetic patients.  
 
All patients included in the study had to give informed consent to partake in the 
study. The informed consent document is listed in Appendix B. Informed consent 
was obtained after the patient reviewed the patient information leaflet. This 
document can be viewed in Appendix C. 
 
Patients partaking in the study were seen early in the morning, long before the start 
of the diabetic clinic. After the data was collected for the research study I also 
managed their regular clinic consultation. They thus benefitted by leaving the clinic 
earlier than on a regular clinic day. 
 
Data collection consisted of face-to-face interviews, review of the patients file for 
their latest treatment, an evaluation of their medication knowledge and collection 
of their latest blood results. They were also questioned and examined for evidence 
of end organ damage ie peripheral vascular disease, stroke, ischaemic heart disease, 
diabetic retinopathy, diabetic neuropathy and diabetic retinopathy. 
 
All the data was collected and recorded by myself using the database software 
package Filemaker Pro
©
 during the interviews. A patient data collection sheet can 
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be viewed in Appendix D. The following information was recorded during the 
face-to-face interviews:  
2.1.2.1. Patient demographics 
The following was recorded under patient demographics: 
1. Date and time of interview. 
2. Patient study number. 
3. Age. 
4. Gender. 
5. Education level (No School, Primary, Secondary, Tertiary). 
6. Highest education level (specific grade or degree). 
7. Helen Joseph Hospital diabetic clinic attendance duration in years. 
8. Duration of diabetes in years. 
9. Co-morbidities. A co-morbidity score was also calculated 
comprising the sum of the patient’s co-morbidities. A co-morbidity 
was listed if the patient volunteered it on questioning or if it was 
found recorded in the patient’s file. 
2.1.2.2. Patients opinion about the risk of diabetes 
The patient was asked how serious they viewed diabetes as a disease.  
Possible responses were: Life threatening, very serious, serious, not so 
serious, not serious at all or not answered.  
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2.1.2.3. Smoking 
The following smoking history was recorded: 
1. Their smoking status: non-smoker, previous smoker, smoker, 
secondary smoker ie a patient exposed to passive smoke from 
another individual or previous secondary smoker. 
2. The amount of cigarettes smoked per day for smokers and 
secondary smokers. 
3. The amount of years smoked for smokers and secondary smokers. 
4. The duration stopped in years was recorded if they had stopped 
smoking. 
2.1.2.4. Questions on employment, income and living conditions 
1. Patients were asked if they were employed or not. If they were 
employed they were also asked if they did night shifts as this is 
listed in the literature as a predictor of poor glycaemic control.
 64 
 
2. They were asked what their net income was per month and also 
asked how many people were supported with that income. The 
average income per person was calculated by taking the net income 
per month and dividing that by the number of individuals supported 
by that income. 
3. Their type of accommodation was recorded. 
4. The number of bedrooms and people living in their dwelling were 
recorded to ascertain the population density. 
5. They were asked if they had a refrigerator, hot water and toilet 
facilities.  
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6. Lastly the patient was asked if they had Internet access in an attempt 
to evaluate learned resourcefulness. 
2.1.2.5. Questions on diabetes management, control and knowledge 
1. Patients were asked how they would rate their overall health. They 
had to pick one from the following scale: Excellent, very good, 
good, average or poor. 
2. Patients were asked to mention things they can do every day to 
improve their glycaemic control. This was an open question and 
they were given time to elaborate. An “improve glucose score” was 
calculated by adding the things they were able to mention. 
3. Patients were asked to name things that are checked at the clinic to 
ensure that they are healthy diabetics. This was an open question 
and they were given no leads. If they mentioned any parameter ie 
cholesterol, blood pressure, glucose on clinic day, HBA1C, weight or 
renal function they were asked to comment on the level of that 
parameter ie if it was high, normal or low for them. They could also 
say that they were not sure and could also choose not to answer the 
question. A “clinic check score” was calculated by adding all the 
things they could mention together.  
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The following values were used to divide the parameters into high, 
normal and low categories:  
      Table 1: Defining parameter categories 
Parameter Low Normal High 
Total cholesterol (mmol/l) < 4.5 < 4.5 ≥ 4.5 
Blood pressure (mmHg)* SBP< 120*  
DBP < 70** 
120  ≥ SBP < 140 
> 70 DBP ≤ 80 
SBP ≥ 140 
DBP ≥ 80 
Glucose (mmol/l) < 4 4 – 8 > 8 
HBA1C (%) < 6.5 6.5 – 7.5 > 7.5 
Weight assessed according to BMI 
(kg/m2) 
< 22 22-25 > 25 
Renal function assessed with eGFR 
(ml/kg/1.73m2)  
< 90 ≥ 90 ≥ 90 
*SBP: Systolic blood pressure, **DBP: Diastolic blood pressure, ^eGFR: Estimated Glomerular 
filtration rate 
4. Patients were asked if they thought they weighed too much for their 
height. Possible responses were yes, no, do not know and not 
answered. 
5. Patients were asked how often they exercised. This was quantified 
as exercise for the purpose of doing exercise. A walk to the mall to 
do their regular grocery shopping or house cleaning did not qualify. 
The type of exercise was not recorded. Possible responses were 
daily, 6,5,4,3, twice or once a week, less often than above, do not 
exercise at all and not answered. 
6. Patients were asked to name all possible complications of diabetes. 
This was an open question. They could mention any of the 
macrovascular complications ie stroke, transient ischaemic attack, 
ischaemic heart disease and peripheral vascular disease; 
microvascular complications ie diabetic retinopathy, nephropathy 
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and neuropathy or diabetic coma complications (coma because of 
hypoglycaemia or hyperglycaemia). A macrovascular complication 
score, microvascular complication score, diabetic coma score and 
total complication score were calculated by adding all the individual 
complications mentioned. 
7. Asking them if they received diabetes education and if they visited a 
dietician in the previous year concluded this section. 
2.1.2.6. Questions on hypo- and hyperglycaemia 
Patients were asked to mention any symptoms of hypoglycaemia (anxiety, 
dizziness, coma, confusion, nausea, palpitations, shakiness, sweating, 
weakness, seizures, pallor) and hyperglycaemia (coma, dizziness, fatigue, 
polyuria, polydipisia, polyphagia). These included ones they might have 
experienced and symptoms they knew about. The questions were open and 
the patients were given time to respond. Subsequently a “hypoglycaemic 
knowledge score” as well as a “hyperglycaemic knowledge score” were 
calculated by adding all the correct answers that were given together. 
 
The patients were asked how many times they experienced symptoms of 
hypoglycaemia in the previous year. The answer was categorized into the 
following: Daily, more than once a week, weekly, once every 2 weeks, 
once every 3 weeks, monthly, every other month, every 3 months, every 3-
6months, less than 6 months, once a year, less than once a year, never and 
not answered.  
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2.1.2.7. Questions on glucose monitoring 
The patient was asked if they used a glucometer. If they did have one they 
were asked to disclose how often they checked their glucose. Glucose 
checking frequency options included: Daily, 2-3 times per week, weekly, 
monthly, check it when I do not feel right or not answered. 
 
In the next phase of the data acquisition, the patient was questioned about 
their current treatment. 
2.1.2.8. Medication identification ability  
An attempt was made to assess patient compliance. A selection of 
medication was placed on a table in the examination room and the patients 
asked to select their medication from this. There was no insulin on the table 
but they were also questioned on their insulin type and dosage. The insulin 
thus also formed part of the final calculation. 
 
They got a mark for every tablet they could identify correctly. They lost 
marks for every tablet that was wrongly identified ie picked from the table 
but not on their prescription. The medication identified correctly was 
calculated as follows:  
(Medication correctly identified  – medication incorrectly identified)  
Total amount of medication taken by the patient presented on the table 
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 Figure 1: Medication used in clinic to assess compliance 
 
The drugs that were used to assess medication identification ability were 
the following: amlodipine 5 mg, adalat XL (nifedipine) 30 mg, aspirin 300 
mg, atenolol 50 mg, atenolol 100 mg, enalapril 10 mg, gliclazide 80 mg, 
indapamide 2.5 mg, metformin 850 mg and perindopril 4 mg. 
2.1.2.9. Barriers to taking treatment 
Patients were asked to mention any barriers to taking their treatment. 
Things like side effects, work schedule, forgetfulness etc. could be 
mentioned here. 
2.1.2.10. Treatment 
The patient’s current treatment was recorded in the database. 
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The next phase of data acquisition entailed a brief examination which 
included the following:  
2.1.2.11. Height 
Height was measured using a stadiometer supplied by the Modern Scale Co 
(Pty) Ltd, (Johannesburg, South Africa). Patients were asked to stand 
upright after removing their shoes and all hair attire before the 
measurement. 
2.1.2.12. Weight 
Weight was measured using a standard calibrated scale. The scale was 
placed on a flat firm surface. Patients were requested to remove their shoes 
and any heavy clothing. The patients were not allowed to hold onto any 
object whilst on the scale. 
2.1.2.13. Waist circumference 
Waist circumference was measured using a tape measure. Patients were 
requested to remove all heavy clothing. Measurement was done with the 
patient standing and taken in a horizontal plane, midway between the 
inferior margin of the ribs and the superior border of the iliac crest. This 
method is recommended by the International Diabetes Federation (IDF) and 
can be accessed on their website (http://www.idf.org). 
2.1.2.14. Neck circumference 
Neck circumference was measured using a measuring tape. All obstructing 
clothing was removed before the measurement. Measurement was done 
with the patient standing. 
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2.1.2.15. Body mass index 
Body mass index was calculated using the following formula: 
Weight (kg)  
Height (m) 
2 
2.1.2.16. Blood pressure 
Blood pressure was taken using a calibrated automatic blood pressure 
monitor. Blood pressure was taken with the patient seated and feet on the 
floor, back supported, arm bared and resting on a surface at heart level. 
Before measurement patients were seated quietly for at least 5 minutes. An 
appropriately sized cuff (encircling 80% of the arm) was used. This is in 
accordance with the guidelines stipulated in the JNC7 and the South 
African hypertension guidelines
 85 ,  91 
.  
 
Although none of the patients were specifically asked to stop smoking, not 
to consume caffeine containing beverages or eat in the previous 30 minutes 
as recommended by the South African hypertension guidelines, it is 
believed that this was not the case for any of the patients in this study
 91 
.  
 
Mean blood pressure was calculated with the following formula: 
(Systolic blood pressure + 2*Diastolic blood pressure)/3  
2.1.2.17. Examination for diabetes complications 
If the patient mentioned any macro- or microvascular complication suffered 
or if it was found during examination it was recorded. 
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Macrovascular complications included any history or clinical examination 
suggestive of stroke, transient ischaemic attack (TIA), ischaemic heart 
disease or peripheral vascular disease. Peripheral vascular disease was 
recorded as a complication if there was evidence of claudication, previous 
amputation or absent foot pulses. 
Microvascular complications included any history or clinical examination 
suggestive of diabetic retinopathy (with direct ophthalmoscopy in the clinic 
or diagnosed by an ophthalmologist), diabetic nephropathy (eGFR < 60 
ml/kg/1.73m
2
 or evidence of microalbuminuria), diabetic neuropathy (if the 
patient was complaining of a burning sensation in their feet or could not 
detect vibration from a 128Hz tuning fork on the medial part of the first 
tarsal bone of either foot), autonomic neuropathy (if the patient volunteered 
any symptom which was consistent, eg impotence).   
 
A “complication score” was calculated for macro- and microvascular 
complications suffered. A “total complication score” was also calculated to 
determine the total amount of complications the patient had experienced. 
Each complication suffered or experienced would add a point to the 
patient’s complication score.  
 
After the brief physical examination, the patients laboratory results were 
recorded.  
2.1.2.18. Laboratory results 
The following laboratory results were recorded with their respective dates.  
1. Glucose measured by finger prick on the day of the clinic visit. 
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2. HBA1C – If the HBA1C value listed on the laboratory system was 
older than 6 months, an HBA1C was taken on the day of the clinic 
visit to satisfy the inclusion criteria of the study.  
3. Lipid profile. 
4. Sodium, potassium, urea and creatinine. 
5. Any urine protein examination listed on the laboratory system ie 
urine albumin/creatinine ratio, urine protein/creatinine ratio. 
Preference was given to albumin/creatinine ratios as these are 
recommended in the 2012 SEMDSA guidelines
 92 
.  
2.2. Statistical analysis 
Patient demographics and clinical characteristics were described and summarized. 
Patients were stratified into two groups: HbA1C above 9.74 % and HbA1C less than or 
equal to 9.74 % (above and below the mean HbA1C for the sample n=100). Groups were 
compared using Student t test (for normally distributed or parametric data) or Kruskal–
Wallis (for not normally distributed or non-parametric data) for continuous variables and 
Chi-square (χ2) test for proportions, where appropriate. A p < 0.05 was considered 
significant. In addition, the correlation between continuous variables was tested and the 
correlation coefficients and p values are presented. 
  
Logistic regression models were used to test the association between the different 
variables and failure to control HbA1C, defined as an HbA1C above 9.74 % vs an HbA1C 
less than or equal to 9.74 %.  Odds ratio (OR) and 95% confidence interval (CI) are also 
presented. Variables identified in the bivariate analysis at p < 0.1 were considered in the 
regression model. In addition alternative definitions of failure to control HbA1C including 
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an HbA1C above 8 % and an HbA1C above 7 % in sensitivity analyses were tested
 3 
. Correlations were done between HBA1C, blood pressure (systolic, diastolic), lipids (total 
and LDL-C, trigycerides as well as HDL-C), body mass index and waist circumference. 
Analyses were performed using the SAS
®
 9.1 statistical software package (SAS Institute, 
Inc., North Carolina, USA) and STATA
TM
 10.1 (StataCorp, Texas, USA).  
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3. CHAPTER 3 – RESULTS 
The data collection for the study started on 3 October 2012 and was concluded on 27 February 
2013, a total span of 168 days. One hundred patients were recruited.  The data was 
independently analysed and verified by Dr. Denise Evans and Arthemon Nguweneza. 
3.0. Description of the study population 
3.0.1. Demographics 
  Table 2: Demographics of the study population 
Characteristic  Sub 
category 
All patients 
(n=100) 
Sub category numbers 
Age (years) Mean (SD)  62.8 (9.7)  
Gender n (%) Male  28 (28%) 
 n (%) Female  72 (72%) 
Duration of diabetes (years) Mean (SD)  15.8 (9.4)  
Diabetic clinic attendance (years) Mean (SD)  10.9 (7.4)  
Education level n (%) Primary  12 (12%) 
 n (%) Secondary  83 (83%) 
 n (%) Tertiary  5 (5%) 
High school education level n (%) Std 6  18 (18%) 
(Secondary education group) n (%) Std 7  9 (9%) 
 n (%) Std 8  28 (28%) 
 n (%) Std 9  11 (11%) 
 n (%) Std 10  15 (15%) 
Total number of co-morbidities Mean (SD)  1.8 (1.1)  
Co morbidity numbers n (%) 0  6 (6%) 
 n (%) 1  36 (36%) 
 n (%) 2  33 (33%) 
 n (%) 3  17 (17%) 
 n (%) 4  6 (6%) 
 n (%) 5  1 (1%) 
 n (%) 6  1 (1%) 
3.0.2. Smoking 
  Table 3: Smoking in the study population 
Characteristic  Sub category All patients 
(n=100) 
 
Sub category 
numbers 
Smoking status n (%) Non smoker  31 (31%) 
 n (%) Smoker  26 (26%) 
 n (%) Secondary smoker  9 (9%) 
 n (%) Previous smoker  35 (35%) 
 n (%) Previous 
secondary smoker 
 1 (1%) 
Smoker: Pack years smoked (years) Mean (SD)  21.5 (15.9) 
(n=26) 
 
Previous smoker: Duration stopped (years) Mean (SD)  18.1 (14.9) 
(n=35) 
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3.0.3. Employment, income and living conditions 
  Table 4: Employment, income and living conditions 
Characteristic  Sub category All patients 
(n=100 unless 
otherwise 
stated) 
Sub category 
numbers 
Employment n (%) Employed  14 (14%) 
 n (%) Not employed  86 (86%) 
Monthly income known (R) Mean (SD)  3247 (3984) 
(n=96) 
 
Mean income per person known (R)* Mean (SD)  1566 (1724) 
(n=96) 
 
Type of accommodation n (%) Flat  22 (22%) 
 n (%) House  77 (77%) 
 n (%) Old age home  1 (1%) 
Number of bedrooms in living unit Mean (SD)  2.5 (0.8)  
Bedroom numbers n (%) 1  11  (11%) 
 n (%) 2  34 (34%) 
 n (%) 3  45 (45%) 
 n (%) 4  10 (10%) 
Number of people per bedroom Mean (SD)  1.5 (0.9)  
People per room numbers n (%) <1  15 (15%) 
 n (%) >=1-2  58 (58%) 
 n (%) >=2-3  19 (19%) 
 n (%) >=3-4  7 (7%) 
 n (%) >=4  1 (1%) 
Hot water n (%)  Yes 91 (91%) 
 n (%)  No 9 (9%) 
Internet access n (%)  Yes 15 (15%) 
 n (%)  No 85 (85%) 
   * Mean income per person = Monthly income / number of dependants 
All the patients had refrigeration and toilet facilities.  
3.0.4. Measurements  
  Table 5: Measurements of study population 
Parameter  All patients 
(n=100) 
Body mass index (kg/m2) Mean (SD) 32.5 (6.4) 
Waist circumference (cm)   Mean (SD) 106.4 (15.0) 
Neck circumference (cm) Mean (SD) 37.8 (3.7) 
Systolic blood pressure (mmHg) Mean (SD) 144.5 (24.2) 
Diastolic blood pressure (mmHg) Mean (SD) 78.0 (13.0) 
Mean blood pressure (mmHg) Mean (SD) 100.2 (14.7) 
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The waist circumference and BMI for the male and female groups were as follows: 
  Table 6: BMI and waist circumference - males and females 
Parameter  Male (n=28) 
 
Female (n=72) 
Body mass index (kg/m2) Mean (SD) 30.13 ( 7.40) 33.37 ( 5.70) 
Waist circumference (cm)   Mean (SD) 106.89 (20.45) 106.13 (12.37) 
 
When omitting the male individual with the largest waist circumference (186cm) 
and BMI (54.90 kg/m
2
), the mean waist circumference and BMI of the male group 
dropped to 103.96 ± 13.6 cm and 29.21 ± 5.69 kg/m
2 
respectively.  The males on 
average thus had smaller BMIs and waist circumferences compared to the females. 
 
3.0.5. Laboratory results  
  Table 7: Laboratory results of study population 
Parameter  All patients 
(n=100) 
Laboratory 
reference range 
(NHLS) 
Glucose on clinic day (mmol/l) Mean (SD) 10.4 (4.8) 3 – 7  
HBA1C (%) Mean (SD) 9.74 (2.2) < 6 
Total cholesterol (mmol/l) Mean (SD) 4.6 (1.3)  
Triglycerides (mmol/l) Mean (SD) 2.1 (1.4) 0.5 – 1.5 
HDL (mmol/l) Mean (SD) 1.2 (0.3)  
LDL (mmol/l) Mean (SD) 2.4 (1.0)  
Urea (mmol/l) Mean (SD) 6.9 (3.8) 2.6 – 7.0 
Estimated glomerular filtration rate 
(ml/min/1.73m2) 
Mean (SD) 83.1 (33.1) > 90 
 
  Table 8: Urine albumin creatinine ratio (ACR) of patients in study population (21 available) 
Parameter   
Urine ACR (mg/mmol) All patients 
(n=21) 
Mean (SD) 3.8 (4.8) 
Urine ACR (mg/mmol) Males (n=6) Mean (SD) 5.56 (7.22) 
Urine ACR (mg/mmol) Females (n=15) Mean (SD) 3.03 (3.49) 
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  Table 9: Urine PCR of patients in the study population (47 available) 
Parameter  n=47 
Urine PCR (g/mmol) Mean (SD) 0.08 (0.22) 
 
3.1. Comparing the group with HBA1C (%) below mean to the group above the mean in 
order to find predictors of glycaemic control 
Part of the inclusion criteria for the study was the availability of a recent HBA1C, ie one 
taken within 6 months of the research clinic date. The mean time between the clinic 
research date and the HBA1C date was 81.8 (64.15) days (Mean (SD). The maximum 
time was 181 days or 5 months and 28 days. 
 
In the following sections tables summarizing the results after grouping the patients into 2 
groups using the mean HBA1C (9.74%) as divider will be shown. Variables with p < 0.1 
were deemed significant enough to include in a logistic regression model. 
3.1.1. Demographics 
  Table 10: Demographic data grouped by HBA1C 
Parameter   
All 
patients 
HBA1C below 
mean 
 (<= 9.74%) 
HBA1C above 
mean 
 (>9.74%) p value 
   (n=100) n=57 n=43   
Age (years) 
Median 
(IQR) 63 (58-70) 64 (60-72) 60 (52-69) 0.045* 
Gender         0.171** 
Male n (%) 28 (28%) 19 (33%) 9 (21%)   
Female n (%) 72 (72%) 38 (67%) 34 (79%)   
   *T-Test, ** Chi-square test 
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  Table 11: Demographic data grouped by HBA1C - continued 
Parameter   
All 
patients 
HBA1C below 
mean 
 (<= 9.74%) 
HBA1C above 
mean 
(>9.74%) p value 
   (n=100) n=57 n=43   
Education level         0.733** 
Primary n (%) 12 (12%) 7 (12%) 5 (12%)   
Secondary  n (%) 83 (83%) 48 (84%) 35 (81%)   
     Std 6 n (%) 18 (18%) 10 (18%) 8 (19%) 0.585** 
     Std 7 n (%) 9 (9%) 4 (7%) 5 (12%)  
     Std 8 n (%) 28 (28%) 16 (28%) 12 (28%)  
     Std 9 n (%) 11 (11%) 5 (9%) 6 (14%)  
     Std 10 n (%) 15 (15%) 12 (21%) 3 (7%)  
Tertiary n (%) 5 (5%) 2 (4%) 3 (7%)  
Duration of diabetes (years) 
Median 
(IQR) 15 (9-21) 17 (10 – 24) 13 (8 – 18) 0.012^ 
Diabetes clinic attendance 
(years) 
Median 
(IQR) 10 (5-15) 10 (5 – 18) 10 (5 –13) 0.105^ 
Co-morbidities            
Hypertension n (%) 86 (86%) 49 (86%) 37 (86%) 0.991** 
Dyslipidemia n (%) 33 (33%) 18 (32%) 15 (35%) 0.728** 
Ischaemic heart disease  n (%) 10 (10%) 4 (7%) 6 (14%)  0.252** 
Osteoarthritis  n (%) 8 (8%) 6 (11%) 2 (5%) 0.284** 
Hypothyroidism  n (%) 6 (6%) 3 (5%) 3 (7%) 0.721** 
GORD n (%) 5 (5%) 2 (4%) 3 (7%) 0.431** 
Total number of co-
morbidities      
0 n (%) 6 (6%) 3 (5%) 3 (7%)  0.629** 
1 n (%) 36 (36%) 21 (37%) 15 (35%)   
2 n (%) 33 (33%) 16 (28%) 17 (40%)   
3 n (%) 17 (17%) 10 (18%) 7 (16%)   
4 n (%) 6 (6%) 5 (9%) 1 (2%)   
5 n (%) 1 (1%) 1 (2%) 0 (0%)   
6 n (%) 1 (1%) 1 (2%) 0 (0%)   
   *T-Test, ^Kruskal Wallis test, ** Chi-square test 
 
Age (p=0.045) and duration of diabetes (p=0.012) both had a p < 0.1.  
Increasing age is cited in the literature as a factor that improves control
 77 
.  
 
Both gender (p=0.171) and duration of diabetes clinic attendance (p=0.105) was 
found not to be significant in this study. 
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A higher level of education was cited in the literature to relate to increased physical 
activity and hence better glycaemic control
 71 
. In this study, education level, even 
after sub-analysis of high school education, was not found to be a significant 
predictor of glycaemic control (p=0.733).  
 
Low-grade systemic inflammation has been cited as a risk factor for developing 
diabetes
 1 
. Low-grade systemic inflammation would only have a bearing on 
inflammatory co-morbidities like rheumatoid arthritis. In this study, co-morbidities 
were not found to be predictors of glycaemic control. This was still the case after 
coding for the most prevalent co-morbidities, volunteered by the patient or 
recorded in the file ie hypertension (n=86), dyslipidaemia (n=33), ischaemic heart 
disease (n=10), osteoarthritis (n=7), hypothyroidism (n=6) and gastro oesophageal 
reflux disease (n=5). The total number of co-morbidities per patient also did not 
code as a predictor of glycaemic control. 
 
The following co-morbidities, presented in decreasing frequency, were volunteered 
by the patient or recorded in the patient’s file: hypertension (n=86), dyslipidemia 
(n=33), ischaemic heart disease (n=10), osteoarthritis (n=7), hypothyroidism (n=6), 
gastro-oesophageal reflux disease (n=5), asthma (n=4), gout (n=4), stroke (n=4), 
congestive cardiac failure (n=3), atrial fibrillation (n=2), chronic kidney disease 
(n= 2), epilepsy (n=2), multinodular goitre (n= 2), previous alcohol abuse (n=2), 
psoriasis (n=2), benign prostate hypertrophy (n=1), chronic obstructive airways 
disease (n=1), colon cancer in remission (n=1), deep venous thrombosis on lifelong 
warfarin (n=1), diverticulosis (n=1), general anxiety disorder (n=1), hay fever 
(n=1), pancreatitis (previous 2
nd
 to alcohol) (n=1), peripheral vascular disease 
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(n=1),  primary hyperparathyroidism (n=1), rheumatoid arthritis (n=1), stasis 
eczema 2
nd
 to varicose veins (n=1) and subclinical hypothyroidism (n=1). 
 
In summary the demographics of this study group shows a picture of an elderly 
group (mean ± standard deviation of 62.8 ± 9.7 years) with a long history of 
diabetes (15.8 ± 9.4) years. The average education level of the group was very low. 
Most of them had secondary education (83%) but when this was examined further 
only 15% of the group had matriculated. Only 5% of the study population had any 
after school training. The patients in the group had a mean co-morbidity count of 
1.8 co-morbidities per patient. 
3.1.2. Opinion about diabetes risk 
Table 12: Opinion about diabetes grouped by HBA1C 
Parameter   All patients 
HBA1C below 
mean (<= 
9.74%) 
HBA1C above 
mean (>9.74%) p value 
   (n=100) n=57 n=43   
Opinion about diabetes risk         0.930** 
Not serious  n (%) 19 (19%)  11 (19%) 8 (19%)    
Life threatening or serious n (%) 81 (81%)  46 (81%) 35 (81%)    
** Chi-square test 
 
The patient’s personal opinion about the risk of diabetes was found not found to be 
significant (p=0.930). 
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3.1.3. Smoking 
  Table 13: Smoking grouped by HBA1C 
Parameter   
All 
patients 
HBA1C below 
mean (<= 
9.74%) 
HBA1C above 
 mean 
(>9.74%) p value 
   (n=100) n=57 n=43   
Smoking status         0.837** 
Non smoker n (%) 31 (31%) 19 (33%) 12 (28%)   
Smoker or Secondary smoker n (%) 34 (34%) 19 (33%) 15 (35%)   
Previous smoker or Previous 
secondary smoker n (%) 35 (35%) 19 (33%) 16(37%)   
Pack years smoked: smokers 
(years) Median (IQR) 18 (10-29) 14 (4 – 29) 10 (8 – 20) 0.471^ 
Duration since stopped 
smoking:  previous smokers 
and secondary smokers (years) Median (IQR) 20 (5-28) 12 (6 – 30) 10 (5 – 25) 0.285^ 
   ^Kruskal Wallis test, ** Chi-square test 
 
Smoking increases insulin resistance according to a study done in 2009
 18 
.  
This was not supported by the data in this study. Smoking status, duration smoked 
and duration stopped were not statistically significant in predicting glycaemic 
control. There was also no evidence to suggest that glycaemic control was 
influenced by being a secondary or previous secondary smoker.  
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3.1.4. Employment, income and living conditions 
  Table 14: Employment, income and living conditions grouped by HBA1C 
Parameter   
All 
patients 
HBA1C below 
mean 
 (<= 9.74%) 
HBA1C above 
mean 
(>9.74%) p value 
   (n=100) n=57 n=43   
Employment         0.991** 
Employed n (%) 14 (14%) 8 (14%) 6 (14%)   
Not employed n (%) 86 (86%) 49 (86%) 37 (86%)   
Mean income per person 
known (R) 
Median 
(IQR) 
1200 
(600-1750) 
1200 
 (600-1750) 
1666 
(700-1700) 0.677^ 
Type of accommodation         0.219** 
Flat n (%) 22 (22%) 10 (18%) 12 (28%)   
House n (%) 77 (77%) 47 (82%) 30 (70%)   
Old age home n (%) 1 (1%) 0 (0%) 1 (2%)   
Number of bedrooms          0.986** 
1 n (%) 11 (11%) 6 (11%) 5 (12%)   
2 n (%) 34 (34%) 20 (35%) 14 (33%)   
3 n (%) 45 (45%) 25 (44%) 20 (47%)   
4 n (%) 10 (10%) 6 (11%) 4 (9%)   
Number of people per bedroom        0.186** 
<1 n (%) 15 (15%) 6 (11%) 9 (21%)   
>=1-2 n (%) 58 (58%) 33 (58%) 25 (58%)   
>=2-3 n (%) 19 (19%) 11 (19%) 8 (19%)   
>=3-4 n (%) 7 (7%) 6 (11%) 1 (2%)   
>=4 n (%) 1 (1%) 1 (2%) 0 (0%)   
Hot water         0.187** 
Yes n (%) 91 (91%) 50 (88%) 41 (95%)   
No n (%) 9 (9%) 7 (12%) 2 (5%)   
Does the patient have access to internet services?    0.381** 
Yes n (%) 15 (15%) 7 (12%) 8 (19%)   
No n (%) 85 (85%) 50 (88%) 35 (81%)   
   ^Kruskal Wallis test, ** Chi-square test 
 
Being employed (p=0.991) and the mean income per person (p=0.677) were found 
not to be statistically significant. It must be noted that the median income per 
person was only R1200.00 per month with an interquartile range of R600.00-
R1750.00. This low income would significantly limit the participant’s ability to 
follow a proper diabetic diet and implement lifestyle modifications necessary. 
These values also suggest that most of the patients had similar income. 
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  Figure 2: Mean income per person 
 
Neither type of accommodation (p = 0.219), number of people per bedroom (p = 
0.186) or having hot water or not (p = 0.187) were statistically significant enough 
to be included in the model.  
 
Learned resourcefulness, which was assessed in this study by questioning the 
patient about Internet access, was also not found not to be statistically significant 
(p=0.381)
 82 
.  
3.1.5. Diabetes management, control and knowledge 
  Table 15: Rating of own health grouped by HBA1C 
Parameter   All patients 
HBA1C below 
mean 
 (<= 9.74%) 
HBA1C above 
mean 
(>9.74%) p value 
   (n=100) n=57 n=43   
How would you rate your 
health?         0.806** 
Excellent n (%) 1 (1%) 0 (0%) 1 (2%)   
Very well n (%) 7 (7%) 4 (7%) 3 (7%)   
Good n (%) 35 (35%) 21 (37%) 14 (33%)   
Average n (%) 49 (49%) 28 (49%) 21 (49%)   
Poor n (%) 8 (8%) 4 (7%) 4 (9%)   
  ** Chi-square test 
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The patients rating of their own health (p=0.806) was not statistically significant 
enough to include in the model.  
 
  Table 16: Diabetes knowledge of ways to improve glucose grouped by HBA1C 
Parameter   All patients 
HBA1C below 
mean 
 (<= 9.74%) 
HBA1C above 
mean 
(>9.74%) p value 
   (n=100) n=57 n=43   
Knowledge on ways to improve glucose at home  
Diet n (%) 82 (82%) 48 (84%) 34 (79%) 0.507** 
Exercise n (%) 62 (62%) 35 (61%) 27 (62%) 0.887** 
Glucose monitoring n (%) 5 (5%) 3 (5%) 2 (5%) 0.889** 
Medication n (%) 33 (33%) 18 (32%) 15 (35%) 0.728** 
Interventions (i.e. weight loss 
or stopping smoking) n (%) 13 (13%) 5 (5%) 8 (8%) 0.148** 
Patient number for each improved glucose score total (adding items together)  0.496** 
0 n (%) 6 (6%) 4 (7%) 2 (5%)   
1 n (%) 22 (22%) 14 (25%) 8 (19%)   
2 n (%) 45 (45%) 24 (42%) 21 (49%)   
3 n (%) 25 (25%) 13 (23%) 12 (28%)   
4 n (%) 2 (2%) 2 (4%) 0 (0%)   
   ** Chi-square test 
 
The patients knowledge of ways to improve glucose at home were not statistically 
significant enough to include in the model (p=0.496).  
 
   Figure 3: Patient numbers versus ways known to improve glucose at home 
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In the above figure it can be seen that 6% of the patients could not mention 
anything which might improve their glucose control. Less than half of the group 
(45%) could mention 2 things to improve glucose control at home. 
 
Table 17: Diabetes knowledge of clinic checks known grouped by HBA1C  
Parameter   All patients 
HBA1C below 
mean 
 (<= 9.74%) 
HBA1C above 
mean 
(>9.74%) p value 
   (n=100) n=57 n=43   
Things to check in clinic to ensure they are healthy diabetics   0.975** 
0 n (%) 22 (22%) 14 (25%) 8 (19%)  
1 n (%) 15 (15%) 9 (16%) 6 (14%)  
2 n (%) 23 (23%) 13 (23%) 10 (23%)  
3 n (%) 27 (27%) 14 (25%) 13 (30%)  
4 n (%) 9 (9%) 5 (9%) 4 (9%)  
5 n (%) 4 (4%) 2 (4%) 2 (5%)  
   ** Chi-square test 
 
Knowledge of things checked in the clinic to make sure that they are healthy 
diabetics were not found to be significant (p=0.975). 
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  Figure 4: Knowledge of clinic checks versus patient numbers 
The knowledge of the patients with respect to things that are measured in the clinic 
to ensure their well-being was very poor. From the figure above it can be seen than 
22 % of the patients could not mention a single clinic check performed to make 
sure that they are healthy. Items mentioned included the following in decreasing 
frequency: 61% mentioned glucose, 41% blood pressure, 26% weight, 16% 
cholesterol, 11% renal function and only 4% mentioned HBA1C. 
 
What was alarming was that the above patients also did not know if their control of 
these parameters was good or bad. The following table lists the result of this 
analysis. The values used to decide if the evaluation was correct are listed in the 
materials and methods section: 
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Table 18: Diabetes knowledge of specific clinic checks known and evaluation result grouped by HBA1C  
Parameter   All patients 
HBA1C below 
mean 
 (<= 9.74%) 
HBA1C above 
mean 
(>9.74%) p value 
   (n=100) n=57 n=43   
Patients able to mention specific clinic 
checks       
Blood pressure n (%) 41 (41%) 21 (37%) 20 (47%) 0.266** 
Blood pressure evaluation 
correct n (%) 28 (28%) 16 (28%) 12 (28%)  
Blood pressure evaluation 
wrong n (%) 13 (13%) 5 (9%) 8 (19%)  
Cholesterol n (%) 16 (16%) 10 (18%) 6 (14%) 0.738** 
Cholesterol evaluation 
correct n (%) 6 (6%) 3 (5%) 3 (7%)  
Cholesterol evaluation wrong n (%) 10 (10%) 7 (12%) 3 (7%)  
Glucose n (%) 61 (61%) 31 (54%) 30 (70%) 0.490** 
Glucose evaluation correct n (%) 38 (38%) 20 (35%) 18 (42%)  
Glucose evaluation wrong n (%) 23 (23%) 11 (19%) 12 (28%)  
HBA1C n (%) 4  (4%) 3 (5%) 1 (2%) 0.248** 
HBA1C evaluation correct n (%) 2 (2%) 1 (2%) 1 (2%)  
HBA1C evaluation wrong n (%) 2 (2%) 2 (4%) 0 (0%)  
Renal function n (%) 11 (11%) 5 (9%) 6 (14%) 0.248** 
Renal evaluation correct n (%) 5 (5%) 3 (5%) 2 (5%)  
Renal evaluation wrong n (%) 6 (6%) 2 (4%) 4 (9%)  
Weight n (%) 26 (26%) 17 (30%) 9 (21%) 0.641** 
Weight evaluation correct n (%) 17 (17%) 12 (21%) 6 (14%)  
Weight evaluation wrong n (%) 9 (9%) 5 (9%) 4 (9%)  
Combinations correct     0.313** 
Blood pressure, glucose, 
cholesterol n (%) 1 (1%) 1 (2%) 0 (0%)  
Blood pressure, glucose n (%) 18 (18%) 13 (23%) 5 (12%)  
Blood pressure, Cholesterol, 
HBA1C n (%) 1 (1%) 1 (2%) 0 (0%)  
Blood pressure, glucose, 
weight n (%) 5 (5%) 4 (7%) 1 (2%)  
   ** Chi-square test 
 
Only 4 patients (4%) could mention that the HBA1C was used to monitor their 
glucose. Of these only 2 of them (50%) were correct with respect to the status of 
their HBA1C.   
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There were very few patients who were able to mention more than one clinic check 
in combination with a correct assessment of its status, ie low, normal or high. From 
the above table it is clear that only a single patient could mention blood pressure, 
cholesterol and HBA1C. 
 
 Table 19: Diabetes complications knowledge grouped by HBA1C  - macrovascular 
 
Parameter   All patients 
HBA1C below 
mean 
 (<= 9.74%) 
HBA1C above 
mean 
(>9.74%) p value 
   (n=100) n=57 n=43   
Macrovascular complications known        
Stroke n (%) 26 (26%) 12 (21%) 14 (33%) 
           
0.194** 
Peripheral vascular disease n (%) 56 (56%) 31 (54%) 25 (58%) 0.708** 
Ischaemic heart disease n (%) 39 (39%) 18 (32%) 12 (49%) 0.080** 
Adding number of macrovascular complications known together  0.166 ** 
0 n (%) 21 (21%) 13 (23%) 8 (19%)  
1 n (%) 45 (45%) 29 (51%) 16 (37%)   
2 n (%) 26 (26%) 13 (23%) 13 (30%)   
3 n (%) 8 (8%) 2 (4%) 6 (14%)   
   ** Chi-square test 
 
  Table 20: Diabetes complications knowledge grouped by HBA1C  - microvascular 
 
Parameter   All patients 
HBA1C below 
mean 
 (<= 9.74%) 
HBA1C above 
mean 
(>9.74%) p value 
   (n=100) n=57 n=43   
Microvascular complications known         
Diabetic retinopathy n (%) 60 (60%) 36 (63%) 24 (56%) 0.458** 
Diabetic neuropathy n (%) 17 (17%) 9 (16%) 8 (19%) 0.711** 
Diabetic nephropathy  n (%) 36 (36%) 19 (33%) 17 (40%) 0.522** 
Autonomic dysfunction n (%) 8 (8%) 6 (11%)  2 (5%) 0.284** 
Adding number of microvascular complications known together  0.996** 
0 n (%) 28 (28%) 11 (19%) 17 (40%)   
1 n (%) 25 (25%) 14 (25%) 11 (26%)   
2 n (%) 33 (33%) 19 (33%) 14 (33%)   
3 n (%) 10 (10%) 6 (11%) 4 (9%)   
   ** Chi-square test 
 
 
 
 
 
 
 
 
  Table 21: Diabetes complications knowledge grouped by HBA1C  - coma 
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Parameter   All patients 
HBA1C below 
mean 
 (<= 9.74%) 
HBA1C above 
mean 
(>9.74%) p value 
   (n=100) n=57 n=43   
Diabetic coma complications known       
Diabetic coma – 
hyperglycemia n (%) 13 (13%) 9 (16%) 4 (9%) 0.339** 
Diabetic coma – 
hypoglycemia n (%) 20 (20%) 12 (21%) 8 (19%) 0.762** 
Adding number of diabetic coma complications known together  0.713** 
0 n (%) 75 (75%) 42 (74%) 33 (77%)   
1 n (%) 17 (17%) 11 (19%) 6 (14%)   
2 n (%) 8 (8%) 5 (9%) 3 (7%)   
   ** Chi-square test 
 
Table 22: Diabetes complications knowledge grouped by HBA1C  - total 
 
Parameter   All patients 
HBA1C below 
mean 
 (<= 9.74%) 
HBA1C above 
mean 
(>9.74%) p value 
   (n=100) n=57 n=43   
Adding number of macro-, micro- and diabetic coma complications known 
together (total) 0.467** 
0 n (%) 6 (6%) 3 (5%) 3 (7%)    
1 n (%) 9 (9%) 4 (7%) 5 (12%)   
2 n (%) 29 (29%) 19 (33%) 10 (23%)   
3 n (%) 28 (28%) 16 (28%) 12 (28%)   
4 n (%) 20 (20%) 13 (23%) 7 (16%)   
5 n (%) 5 (5%) 2 (4%) 3 (7%)   
6 n (%) 2 (2%) 0 (0%) 2 (5%)   
7 n (%) 1 (1%) 0 (0%) 1 (2%)   
   ** Chi-square test 
  
Knowledge of diabetic complications, macrovascular (p=0.166), microvascular 
(p=0.996) and diabetic coma complications (p=0.996) were not statistically 
significant. Knowledge of ischaemic heart disease (p=0.080) was significant 
enough but patient numbers in this subgroup were insufficient for the logistic 
regression model.  
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Knowledge of diabetes complications was poor in the study population. Twenty 
one percent could not mention a single macrovascular event, 32% not a single 
microvascular event and 75% not a single diabetic coma complication. 
 
Table 23: Height for weight evaluation grouped by HBA1C 
 
Parameter   All patients 
HBA1C below 
mean 
 (<= 9.74%) 
HBA1C above 
mean 
(>9.74%) p value 
   (n=100) n=57 n=43   
For your height, do you think you weigh too much?   0.400** 
No, evaluation correct n (%) 12 (12%) 9 (16%) 3 (7%)  
No, evaluation wrong n (%) 37 (37%) 21 (37%) 16 (37%)  
      
   ** Chi-square test 
 
 
The patient’s insight with respect to his or her own weight was not found to be a 
significant predictor of glycaemic control (p=0.400). Interestingly enough, all the 
patients who answered “yes” to the question: “Do you think you weigh too much 
for your height?” (n=46) were correct in their assessment. A body mass index of 
22-25 kg/m
2
 was used as normal for this assessment. 
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  Table 24: Exercise frequency, diabetes education and dietician visit grouped by HBA1C  
Parameter   All patients 
HBA1C below 
mean 
 (<= 9.74%) 
HBA1C above 
mean 
(>9.74%) p value 
   (n=100) n=57 n=43   
Exercise frequency         0.773** 
Daily n (%) 30 (30%) 16 (28%) 14 (33%)   
6 times per week n (%) 0 (0%) 0 (0%) 0 (0%)   
5 times per week n (%) 2 (2%) 0 (0%) 2 (5%)   
4 times per week n (%) 3 (3%) 1 (2%) 2 (5%)   
3 times per week n (%) 11 (11%) 8 (14%) 3 (7%)   
2 times per week n (%) 11 (11%) 5 (9%) 6 (14%)   
Once a week n (%) 3 (3%) 2 (4%) 1 (2%)   
Less often than above n (%) 21 (21%) 14 (25%) 7 (16%)   
No exercise at all n (%) 18 (18%) 10 (18%) 8 (19%)   
Not answered n (%) 1 (1%) 0 1 (2%)   
Did the patient receive diabetes education at Helen Joseph Hospital 
diabetic clinic?    0.871** 
Yes n (%) 34 (34%) 19 (33%) 15 (35%)   
No n (%) 66 (66%) 38 (67%) 28 (65%)   
Did the patient see a dietician in the previous year?      0.628** 
Yes n (%) 70 (70%) 41 (72%) 29 (67%)   
No n (%) 30 (30%) 16 (28%) 14 (33%)   
   ** Chi-square test 
 
Self-reported exercise frequency was not significant in this study (p=0.773) even 
though previous studies have shown benefit
 68 , 70 - 72 
. This might be due to error in 
self-reporting. Exercise type and duration was not questioned and these might be 
confounders. 
 
Diabetes education (p=0.871) and the input of a dietician in the previous year 
(p=0.628) were not statistically significant. In previous studies diabetes education 
and knowledge was cited to be a factor that would improve control
 76 
.  
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3.1.6. Hypo-and hyperglycaemia 
  Table 25: Hypo- and hyperglycaemia grouped by HBA1C 
Parameter   All patients 
HBA1C below 
mean 
 (<= 9.74%) 
HBA1C above  
mean 
(>9.74%) p value 
   (n=100) n=57 n=43   
Hypoglycaemia symptoms known or experienced   
Dizziness n (%) 56 (56%) 31 (54%) 25 (58%) 0.708** 
Hunger n (%) 14 (14%) 7 (12%) 7 (16%) 0.568** 
Nausea n (%) 7 (7%) 4 (7%) 3 (7%) 0.994** 
Sweating n (%) 23 (23%) 12 (21%) 11 (26%) 0.594** 
Weakness n (%) 30 (30%) 17 (30%) 13 (30%) 0.965** 
Coma  n (%) 15 (15%) 10 (18%) 5 (12%) 0.412** 
Headache n (%) 7 (7%) 4 (7%) 3 (7%) 0.994** 
Confusion n (%) 24 (24%) 9 (16%) 15 (35%) 0.030** 
Shakiness/palpitations n (%) 36 (36%) 17 (30%) 18 (42%) 0.212** 
Knowledge or experience of the above hypoglycaemic symptoms  0.575** 
0 n (%) 6 (6%) 4 (7%) 2 (5%)   
1 n (%) 20 (20%) 11 (19%) 9 (21%)   
2 n (%) 38 (38%) 25 (44%) 13 (30%)   
3 n (%) 28 (28%) 15 (26%) 13 (30%)   
4 n (%) 8 (8%) 4 (7%)  4 (9%)   
Hypoglycaemic episodes frequency    0.094** 
Monthly n (%) 64 (66%) 41 (75%) 23 (55%)   
Less than monthly n (%) 14 (14%) 7 (13%) 7 (17%)   
Never n (%) 19 (20%) 7 (13%) 12 (28%)   
Hypoglycaemic episodes frequency  0.051** 
Less than monthly or monthly n (%) 78 (14%) 48 (87%) 30 (71%)  
Never n (%) 19 (20%) 7 (13%) 12 (29%)  
Number of hyperglycaemic symptoms experienced or known   
Coma n (%) 2 (2%) 2 (4%) 0 (0%) 0.100** 
Dizziness n (%) 24 (24%) 12 (21%) 12 (28%) 0.116** 
Fatigue n (%) 20 (20%) 11 (16%) 9 (21%) 0.226** 
Polydipsia n (%) 18 (18%) 12 (21%) 6 (14%) 0.235** 
Polyphagia n (%) 0 (0%) 0 (0%) 0 (0%) 0 
Polyuria  n (%) 3 (3%) 1 (2%) 2 (5%) 0.731** 
Knowledge/experience of the above hyperglycaemic symptoms    0.662**  
0 n (%) 41 (41%) 23 (40%) 18 (42%)  
1 n (%) 48 (48%) 29 (51%) 19 (44%)   
2 n (%) 10 (10%) 5 (9%) 5 (12%)   
3 n (%) 1 (1%) 0 (0%) 1 (2%)   
  ** Chi-square test 
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Hypoglycaemic episode frequency was found to be statistically significant 
(p=0.094) but knowledge of hypoglycaemic (p=0.575) and hyperglycaemic 
symptoms (p=0.662) were not. 
3.1.7. Glucose monitor and use 
 Table 26: Glucose monitor and use grouped by HBA1C 
Parameter   
All 
patients 
HBA1C below 
mean 
 (<= 9.74%) 
HBA1C above 
mean 
(>9.74%) p value 
   (n=100) n=57 n=43   
Patient has glucose monitor         0.994** 
Yes n (%) 93 (93%) 53 (93%) 40 (93%)   
No n (%) 7 (7%0 4 (7%) 3 (7%)   
How often glucose checked?         0.990** 
Daily n (%) 71 (81%) 41 (82%) 30 (79%)   
More than daily n (%) 17 (19%) 9 (18%) 8 (21%)   
  ** Chi-square test 
 
Having a glucose monitor (p=0.994) and frequency of glucose checks (p=0.990) 
did not seem to have statistical significance. This is in contrast to the literature 
supporting the notion that self-monitoring of glucose improves control
 79 
. A 
possible confounder here is that the patients in this study most likely did not know 
what their glucose control should be. This is based on the poor level of knowledge 
with respect to diabetes found in the study population. Having a monitor without 
knowledge of glucose targets would be futile. Knowledge of specific glucose 
targets was not tested during my interview. 
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3.1.8. Treatment  
  Table 27: Treatment grouped by HBA1C 
Parameter   
All 
patients 
HBA1C below 
mean  
(<= 9.74%) 
HBA1C above 
 mean 
(>9.74%) p value 
   (n=100) n=57 n=43   
Identification of prescribed medication          
    Correct (100%) n (%) 78 (78%) 46 (81%) 32 (74%) 0.453** 
    Incorrect (< 100%) n (%) 22 (22%) 11 (19%) 11 (26%)  
Concomitant medication       
Metformin     0.330* 
       Not on metformin  n (%) 26 (26%) 17 (30%) 9 (21%) 0.330** 
       500 mg BD n (%) 1 (1%) 0 (0%) 1 (2%)  
       Other (i.e. 850 mg/day, 850mg                       
        BD, 1g BD) n (%) 73 (73%) 40 (70%) 33 (77%)  
Simvastatin          0.099** 
    Not on statin n (%) 10 (10%) 8 (14%) 2 (5%)  
    Simvastatin 20 mg/day  n (%) 62 (62%) 37 (65%) 25 (58%)  
    Simvastatin 40 or 80 mg/day n (%) 28 (28%) 12 (21%) 16 (37%)  
Aspirin     0.079** 
    Not on aspirin   n (%) 7 (7%) 3 (5%)  4 (9%)            
    75 mg/day n (%) 78 (78%) 49 (86%) 29 (67%)  
    150 mg/day n (%) 15 (15%) 5 (9%) 10 (23%)  
Insulin regimen         0.622** 
    No insulin n (%) 6 (6%) 3 (%) 3 (7%)   
    Once daily insulin n (%) 9 (9%) 5 (9%) 4 (9%)   
    Twice daily insulin n (%) 67 (67%) 41 (72%) 26 (60%)   
    Basal bolus insulin n (%) 18 (18%) 8 (14%) 10 (23%)   
  *T-Test, ** Chi-square test 
 
Most of the patients (n=78) were able to identify their medication without any 
errors. This finding was remarkable but not significant with respect to predicting 
glycaemic control (p=0.453). 
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Figure 5: Medication identification ability and number of patients able to achieve it 
 
The dosage of simvastatin (p=0.099) and aspirin (p=0.079) were significant enough 
to include in the model. Insulin regime (p=0.622) and metformin dosage (p=0.330) 
did not have an impact on predicting glycaemic control. 
 
The following barriers to taking treatment, in decreasing frequency, were 
volunteered by the patients: Forget to take medication at times (n=8), nausea 
secondary to metformin (n=3), difficult to take medication when there is nothing to 
eat (n=2), difficult to take medication at work due to work schedule (n=2), tired of 
taking large amounts of medication (n=2), nifedipine gives nightmares (n=1), 
allergy to aspirin (n=1), confusion between own and mother’s medication at times, 
both have diabetes (n=1), cough secondary to ACE inhibitor (n=1),  dizziness 
secondary to perindopril (n=1), metformin tablet is too big (n=1), sometimes too 
tired to take medication (n=1).  
Seventy-six patients did not report any barrier to taking their medication. 
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3.1.9. Measurements and examination 
 Table 28: Measurements grouped by HBA1C 
Parameter   
All 
patients 
HBA1C below 
mean 
(<= 9.74%) 
HBA1C above 
 mean 
 (>9.74%) p value 
   (n=100) n=57 n=43   
Body mass index (kg/m2) 
Median 
(IQR) 
32 
(28-35) 
32 
(27-35) 
32.3  
(29-35) 0.833* 
     < 25 kg/m2 n (%) 12 (12%) 6 (21%) 6 (8%) 0.006* 
     25 – 30 kg/m2 n (%) 18 (18%) 9 (32%) 9 (13%)  
     ≥ 30 kg/m2 n (%) 70 (70%) 13 (47%) 57 (79%)  
Waist circumference (cm) 
Median 
 (IQR) 
104.5 
 (97-114) 
104 
(97-116) 
105 
(98-113) 0.956^ 
     < 94 cm for males; 
     < 80 cm for females n (%) 6 (6%) 5 (9%) 1 (2%) 0.179^ 
     ≥ 94 cm for males; 
     ≥ 80 cm for females n (%) 94 (94%) 52 (91%) 42 (98%)  
Neck circumference (cm) 
Median 
(IQR) 
37.5 
(35-40.5) 
37.5 
(35-40) 
37 
(35-40) 0.914^  
Systolic blood pressure 
(mmHg) 
Median 
(IQR) 
140.0 
(127.5-
160.5) 
138 
(126-156) 
145 
(132-165) 0.436* 
Diastolic blood pressure 
(mmHg) 
Median 
(IQR) 
77 
(68-86) 
74 
(67-80) 
81 
(74-90) 0.002* 
     < 70 mmHg n (%) 26 (26%) 19 (33%) 7 (16%) 0.054* 
     ≥ 80 mmHg  n (%) 38 (38%) 15 (26%) 23 (54%) 0.006* 
Glucose on clinic day 
(mmol/l) 
Median 
(IQR) 
10 
(7-12) 
9.2 
(7.1-12) 
10.6 
(7.3-12.8) 0.493^ 
  *T-Test, ^Kruskal Wallis test, ** Chi-square test 
 
Although both BMI and waist circumference are supported as predictors of 
glycaemic control in the literature only BMI (p=0.006) was found to be statistically 
significant in this study
 11 , 68 
.  Diastolic blood pressure (p=0.002) was found to be 
statistically significant but neck circumference (p=0.914), systolic blood pressure 
(p=0.436) and finger prick glucose measurement on the clinic day (p=0.493) were 
not significant in predicting glycaemic control. 
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  Table 29: Complications experienced grouped by HBA1C 
 
Parameter   
All 
patients 
HBA1C below 
mean 
(<= 9.74%) 
HBA1C above 
 mean 
 (>9.74%) p value 
   (n=100) n=57 n=43   
Macrovascular complications experienced         
Transient ischaemic attack n (%) 5 (5%) 4 (7%) 1 (2%) 0.287** 
Stroke  n (%) 3 (3%)   2 (4%) 1 (2%)   0.737** 
Peripheral vascular disease n (%) 5 (5%) 3 (5%) 2 (4%) 0.889** 
Ischaemic heart disease n (%) 14 (14%) 6 (11%) 8 (19%) 0.249** 
Individual numbers           
0 n (%) 75 (75%) 44 (77%) 31 (72%)  0.304** 
1 n (%) 23 (23%) 11 (19%) 12 (28%)   
2 n (%) 2 (2%) 2 (4%) 0 (0%)   
Microvascular complications experienced         
Diabetic retinopathy n (%) 11 (11%) 6 (11%) 5 (12%) 0.861** 
Diabetic neuropathy n (%) 39 (39%) 22 (39%) 17 (40%) 0.924** 
Diabetic nephropathy  n (%) 47 (47%) 29 (51%) 18 (42%) 0.371** 
Autonomic dysfunction n (%) 11 (11%) 8 (14%) 3 (7%) 0.264** 
Individual numbers         0.052** 
0 n (%) 28 (28%) 11 (19%) 17 (40%)   
1 n (%) 42 (42%) 29 (51%) 13 (30%)   
2 n (%) 24 (24%) 15 (26%) 9 (21%)   
3 n (%) 6 (6%) 2 (4%) 4 (9%)   
Total number of complications experienced (macrovascular + microvascular)  0.04**  
0 n (%) 21 (21%) 7 (12%) 14 (33%)   
1 n (%) 42 (42%) 29 (51%) 13 (30%)   
2 n (%) 21 (21%) 14 (25%) 7 (16%)   
3 n (%) 13 (13%) 5 (9%) 8 (19%)   
  *T-Test, ^Kruskal Wallis test, ** Chi-square test 
 
The number of microvascular (p=0.052) and total complications (p=0.04) suffered 
was significant but the number of macrovascular complications suffered (p=0.304) 
did not show any statistical significance. 
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3.1.10. Laboratory values  
  Table 30: Laboratory values grouped by HBA1C 
Parameter   All patients 
HBA1C below 
mean 
(<= 9.74%) 
HBA1C above 
mean 
(>9.74%) p value 
   (n=100) n=57 n=43   
Total cholesterol (mmol/l) Median (IQR) 4.4 (3.6-5.4) 4.2 (3.6-5.3) 4.7 (3.7-5.7) 0.223^ 
    ≥  4.5 mmol/l n (%) 50 (50%) 25 (44%) 25 (58%) 0.157^ 
Triglycerides (mmol/l) Median (IQR) 1.8 (1.2-2.5) 1.7 (1.2-2.3) 1.9 (1.5-2.9) 0.285^ 
     ≥ 1.7 mmol/l n (%) 57 (57%) 29 (51%) 28 (65%) 0.155^ 
HDL-C(mmol/l) Median (IQR) 1.1 (0.9-1.4) 1.1(0.9-1.4) 1.9 (1.5-2.9) 0.785^ 
     < 1 mmol/l for males; 
     < 1.2 mmol/l for females n (%) 46 (46%) 27 (47%) 19 (44%) 0.752^ 
LDL-C (mmol/l) Median (IQR) 2.3 (1.7-3.1) 2.2 (1.6-2.9) 2.6 (1.9-3.3) 0.189^ 
      1.8 – 2.5 mmol/l n (%) 29 (29%) 18 (33%) 11 (26%) 0.320^ 
      ≥ 2.5 mmol/l n (%) 42 (42%) 20 (37%) 22 (52%)  
Urea (mmol/l) Median (IQR) 6 (5-8) 6.3 (4.9-7.9) 5.2 (4.5-7.4) 0.133^ 
      ≥ 7 mmol/l n (%) 37 (37%) 24 (42%) 13 (30%) 0.223^ 
Glomerular filtration rate 
(ml/min/1.73m2) Median (IQR) 80 (61-98) 71 (58.5-93) 88 (67-117) 0.0524^ 
     < 60 ml/min/1.73m2 n (%) 25 (25%) 16 (28%) 9 (21%) 0.414^ 
Urine PCR (g/mmol) 
Median 
 (IQR) 
0.02 
(0.01-0.07) 
0.02 
(0.01-0.08) 
0.03 
(0.01-0.06) 0.9293^ 
^Kruskal Wallis test 
 
eGFR (p=0.0524) were found to be significant enough to include in the logistic 
regression model. 
Total cholesterol (p=0.223), triglycerides (p=0.285), LDL-C (p=0.189), urea 
(p=0.133), HDL-C (p=0.785) and urine PCR (p=0.9293) were not significant 
enough to include.  
3.2. Logistic regression model results 
Variables from the table comparing the group with HBA1C below 9.74 % with the group 
above were used in a logistic regression model if they had a p value < 0.1. Variables with 
p ≥ 0.1 were deemed not to be statistically significant enough and were excluded from 
further analysis.  
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The following table lists the result of the logistic regression model. The table lists the 
crude odds ratio as well as the adjusted odds ratio. The adjusted odds ratio takes all the 
variables listed in the table into account. Confidence intervals crossing 1.0 make a result 
less significant as it supports harm and benefit at the same time.  If a confidence interval 
is wide it limits the reliability of a result, if it crosses one no results can be drawn. Larger 
sample size might influence confidence intervals. All results viewed should bear this in 
mind. 
 
Even though gender had a p = 0.171 it was also included in the model. 
 
Table 31: Logistic regression analysis of variables with p < 0.1 – demographic analysis  
Variable  n (%) Crude OR (95% CI) Adjusted OR (95% CI) 
        
Age    
< 50yrs 10 (10%) 1 1 
≥ 50 yrs 90 (90%) 0.29 (0.069-1.178) 0.37 (0.06-2.26) 
    
Gender    
Male 28(28%) 1 1 
Females 72 (72%) 1.89 (0.75 – 4.73) 2.62 (0.72-9.55) 
    
Duration of diabetes (years)    
≥ 10 yrs 73 (73%) 1 1 
< 10 yrs 27 (27%) 1.63 (0.67 – 3.97) 1.36 (0.37-5.02) 
 
Age 
If you are over 50, the model predicts that you will have 63% better control compared to a 
person younger than 50. This is supported by the adjusted odds ratio of 0.37.  
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Gender 
Gender was included in the model even though it had a p value of 0.733 in the table 
comparing groups with HBA1C above and below the mean. This was done to ensure that 
gender bias does not confound the final result. 
Duration of diabetes 
Having diabetes for less than 10 years predicts worse control. The adjusted odds ratio 
revealed that control would be 1.36 times worse.  
 
Table 32: Logistic regression analysis of variables with p < 0.1 – hypoglycaemic frequency 
 
Variable  n (%) Crude OR (95% CI) Adjusted OR (95% CI) 
    
Hypoglycaemic episodes frequency    
Never 19 (20%) 1 1 
Monthly or Less than monthly 78 (80%) 0.35 (0.12-1) 0.31 (0.09-1.10) 
* Statin low: 20 mg Simvastatin daily, Statin high: 40mg or 80mg Simvastatin daily 
 
Hypoglycaemic episode frequency 
Patients with more frequent hypoglycaemic episodes had better control compared to 
patients who have never had a hypoglycaemic episode. The model revealed a 69% 
reduction in HBA1C for patients having monthly or fewer hypoglycaemic episodes 
compared to those who never experienced this phenomenon. Although the confidence 
interval was narrow, it did cross 1.0. This makes the result less significant. 
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Table 33: Logistic regression analysis of variables with p < 0.1 – treatment analysis  
Variable  n (%) Crude OR (95% CI) Adjusted OR (95% CI) 
    
Aspirin dosage    
< 150 mg 85 (85%) 1 1 
≥ 150 mg 15 (15%) 3.15 (0.99-10) 6.47 (1.60-26.05) 
    
Simvastatin dosage*    
No statin 10 (10%) 1 1 
Statin Low 62 (62%) 2.7 (0.529-13.800) 2.35 (0.31 -18.10) 
Statin High 28 (28%) 5.3 (0.954-29.807) 6.97 (0.84 -58.15) 
* Statin low: 20 mg Simvastatin daily, Statin high: 40mg or 80mg Simvastatin daily 
 
Aspirin dosage 
Having the patient on an aspirin dosage ≥ 150 mg per day predicted 6.47 times worse 
control. Although the confidence interval is wide (1.60-26.05), it does not cross 1.0 and 
therefore makes this finding significant. 
Simvastatin dosage 
A higher dosage of statin predicted worse glycaemic control. Confidence intervals were 
wide and crossed 1.0 but 20mg of simvastatin daily predicted 2.35 times worse control, 
and 40mg to 80mg of simvastatin daily predicted 6.97 times worse control when 
compared to no simvastatin. This might indicate that patients with poorer control also 
have more challenging lipid control and in this case would receive a higher dose of statin 
to achieve adequate lipid control.  
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Table 34: Logistic regression analysis of variables with p < 0.1 – measurement analysis 
Variable  n (%) Crude OR (95% CI) Adjusted OR (95% CI) 
    
Body mass index    
<= 25 kg/m2 12 (12%) 1 1 
> 25 kg/m2 88 (88%) 1.30 (0.72-2.35) 1.09 (0.49-2.41) 
    
Diastolic Blood pressure (mmHg)    
< 70 mmHg 26 (26%) 1 1 
≥ 70 mmHg 76 (76%) 2.57 (0.97-6.85) 2.80 (0.80-9.78) 
 
Body mass index 
The literature supports weight loss as a measure to improve glycaemic control
 11 , 68 
. This 
notion is supported by the results in the model. A body mass index of more than 25 kg/m
2
 
predicted slightly worse control (adjusted odds ratio of 1.09). The confidence interval is 
unfortunately very wide and crosses 1.0, which reduces the statistical significance. 
Diastolic blood pressure 
An increase in diastolic blood pressure above 70 predicted 2.80 times worse glycaemic 
control.  
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Table 35: Logistic regression analysis of variables with p < 0.1 – laboratory analysis 
Variable  n (%) Crude OR (95% CI) Adjusted OR (95% CI) 
    
Estimated glomerular filtration rate    
< 60 ml/min/1.73m2 25 (25%) 1 1 
≥ 60 ml/min/1.73m2  75 (75%) 1.47 (0.58-3.75) 0.90 (0.25-3.27) 
 
Estimated glomerular filtration rate 
According to the analysis the crude odds ratio supports better control with a low eGFR 
and the adjusted odds ratio supports worse control with a low eGFR. The confidence 
intervals for both the crude and adjusted odds ratios cross 1.0, limiting the statistical 
significance. 
 
 
Table 36: Logistic regression analysis of variables with p < 0.1 – complication count 
Variable  n (%) Crude OR (95% CI) Adjusted OR (95% CI) 
    
Microvascular complication count    
No complication 28 (28%) 1 1 
Complications 72 (72%) 0.37 (0.15-0.90) 0.73 (0.11-5.07) 
    
Total complication count    
No complication 21 (22%) 1 1 
Complications 76 (78%) 0.29 (0.11-0.81) 0.56 (0.07-4.38) 
 
Microvascular and total complications suffered 
It seems that one of the implications of developing a diabetic complication is an 
improvement in glycaemic control. Suffering any complication improves glycaemic 
control by 44% according to the crude odds ratio. A microvascular complication suffered 
improves glycaemic control by 27% compared to no microvascular complication 
suffered. For both these variables, the confidence interval crossed 1.0, which made the 
result less significant.  
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3.3. Logistic regression model with HBA1C of 8.0 % and 7.0% as cut off 
An attempt was made to do sensitivity analysis of the logistic regression model by 
changing the dividing HBA1C value to 8.0 % and 7.0 % respectively. 
 
In this study there were only 20 patients with an HBA1C ≤ 8.0% and 7 patients with a 
HBA1C ≤ 7.0%. Due to the small patient numbers in these groups the models did not 
reveal any significant result.  
3.4. Correlations between HBA1C, blood pressure, lipids, waist circumference and BMI 
Correlations were done between HBA1C, blood pressure, lipids, waist circumference and 
body mass index. The table with the results can be viewed in Appendix E.  
The significant correlations with p < 0.05 are highlighted in this section. 
 
There was a positive correlation between HBA1C and diastolic blood pressure with an r-
value of 0.29981 (p = 0.0024).  This means for an increase of HBA1C by 1 % the diastolic 
blood pressure would increase by a factor of 0.29981. 
 
Diastolic blood pressure had 2 significant correlations. The correlation with HBA1C is 
described above. The second correlation was a positive correlation with the triglyceride 
level. The r-value was 0.35611 (p=0.0003).  
 
There was an expected positive correlation between the body mass index and waist 
circumference with an r-value of 0.82496 (p < 0.0001). There were no other significant 
correlations with these two variables. 
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3.5. Comparing diabetic clinic treatment targets, treatment prescribed and laboratory 
investigation frequency against the 2012 SEMDSA guidelines 
3.5.1. Clinic treatment targets against 2012 SEMDSA guidelines 
3.5.1.1. Waist circumference 
SEMDSA guidelines for waist circumference 
The 2012 SEMDSA guideline recommends a waist circumference of less 
than 80 cm for females and less than 94 cm for males
 93 
.  
Waist circumference in the study group 
 Table 37: Waist circumference of the study group 
 Males (n=28) Females (n=72) 
Waist circumference < 94 cm ≥ 94 cm < 80 cm ≥ 80 cm 
Patient numbers n=6 n=22 n=0 n=72 
Percentage 21% 79% 0% 100% 
  
From the table it is clear that the majority of the patients in this study did 
not meet the 2012 SEMDSA waist circumference targets for Type 2 
diabetes.  
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3.5.1.2. Blood pressure 
2012 SEMDSA guidelines for blood pressure 
The 2012 SEMDSA guidelines recommend a systolic blood pressure of 
120-140 mmHg and a diastolic blood pressure of 70-80 mmHg
 84 
.  
Blood pressures found in the study group 
Table 38: Blood pressure in the study group 
 Blood pressure 
lower than 
guideline blood 
pressure 
Blood pressure 
meets guideline 
blood pressure 
Blood pressure 
higher than 
guideline blood 
pressure 
Total n=22 (22%) n=15 (15%) n=63 (63%) 
Receiving 
hypertension 
treatment 
n=19 (86%) n=12 (80%) n=58 (92%) 
Not receiving 
hypertension 
treatment 
n=3 (14%) n=3 (20%) n=5 (8%) 
 
Sub analysis of the group of 63 with blood pressures higher than the 2012 
SEMDSA guidelines are depicted in the following table: 
Table 39: Blood pressure in cohort with SBP ≥ 140 and DBP ≥ 80 
Blood pressure group SBP ≥ 140 DBP ≥ 80 
Blood pressure group DBP < 80 DBP ≥ 80 SBP < 140 
Patient numbers n=25 n=27 n=11 
Not receiving hypertension treatment n=3 (12%) n=0 (0%) n=2 (18%) 
 
Blood pressure conclusion 
Firstly it must be noted that the above analysis was done on a single clinic 
blood pressure measurement. This is not a proper way of diagnosing 
hypertension. It must also be noted that there could be a couple of possible 
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confounders specific to these measurements. The latest South African 
hypertension guidelines, published in 2006, specify that the blood pressure 
must only be taken after the patient has rested for at least 5 minutes. It must 
be taken with the patient seated and with feet resting on the floor. It also 
specifies that the blood pressure must not be taken if the patient smoked, 
drank a caffeine-containing beverage or ate in the previous 30 minutes
 91 
. 
Although blood pressures were taken with the patient seated, it was not 
recorded if any of the other criteria were met. Apart from this, it was also 
not recorded if the patients took their treatment on the morning of the clinic 
visit. This in itself might have an impact on the blood pressure reading.  
 
With the above in mind, this single blood pressure measurement used for 
analysis revealed that 15% of the patients were at blood pressure goal 
according to the 2012 SEMDSA guideline. This means 85% were not at 
goal.  
 
86% of the 22 patients with blood pressure lower than the recommended 
level did receive treatment for hypertension. These patients were over 
treated for hypertension.  
 
Most of the patients with blood pressure above the recommended level 
were treated for hypertension. In the subgroup with systolic blood pressure 
≥ 140 mmHg and diastolic blood pressure < 80 mmHg only 12% (3/25) 
were not treated. In the subgroup with systolic blood pressure ≥ 140 mmHg 
and diastolic blood pressure ≥ 80 mmHg every single patient received 
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hypertension treatment. In the subgroup with diastolic blood pressure ≥ 80 
mmHg and systolic blood pressure <140 mmHg 2/11 (18%) did not receive 
treatment for hypertension. 
3.5.2. Treatment prescribed 
3.5.2.1. Aspirin therapy 
2012 SEMDSA guidelines for aspirin use 
Aspirin (75-300 mg once daily) is indicated for secondary prevention in all 
patients with established cardiovascular disease. It is recommended as 
primary prevention for all patients with more than 10% cardiovascular risk 
over 10 years
 94 
.  
Aspirin use in the study group 
In the study group of 100 patients, 93 had a prescription for aspirin. 
Aspirin not prescribed group 
Of the 7 patients found in this group 1 patient reported an allergy to aspirin.  
The remaining 6 did qualify for aspirin therapy according to the 2012 
SEMDSA guidelines. This means 6/7 or 86% of patients who didn’t have a 
prescription for aspirin qualified for aspirin therapy.  
Aspirin prescribed group 
93 of the 100 patients in the study did receive aspirin. The results are 
depicted in the following table:  
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 Table 40: Aspirin use in the study group versus SEMDSA guidelines 
 Male Female  
Patient group Male <= 50 
years 
Male > 50 
years 
Female <= 60 
years 
Female > 60 
years 
Total 
Patients on 
aspirin 
5 19 27 42 93 
Patient should 
not be on 
aspirin 
5 1  25 0 31 
Percentage error 100% 5% 93% 0% 33% 
 
Aspirin conclusion 
From the above it can be seen that 86% of the patients who did not have a 
prescription for aspirin qualified for it.  
In the group who did receive aspirin, 33% did not qualify according to the 
SEMDSA 2012 guidelines
 94 
. This error was more marked in the younger 
age group: 100% versus 5% for males and 93% versus 0% for females. 
3.5.2.2. Prescription of statins and lipid goals 
2012 SEMDSA guidelines for lipids 
The 2012 SEMDSA guidelines recommend the following lipid targets: 
Total cholesterol: < 4.5 mmol/l 
LDL cholesterol: < 1.8 mmol/l (< 2.5 mmol/l if the patient has no 
cardiovascular disease, no chronic kidney disease, is under 40 years of age 
or has a duration of diabetes which is less than 10 years and has no other 
cardiovascular risk factors) 
HDL cholesterol: > 1.0 mmol/l (men) and > 1.2 mmol/l (women) 
Triglycerides: <1.7 mmol/l
 86 
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The primary goal is to achieve the LDL-C target and statins are the first line 
therapy to achieve this. Statins are also indicated for all Type 2 diabetes 
patients with the following criteria irrespective of LDL-C level: 
 Have existing cardiovascular disease 
 Have chronic kidney disease (eGFR < 60ml/min/1.73m2) 
 Are older than 40 years of age or have had diabetes for longer than 
10 years, with one or more additional cardiovascular risk factor
 86 
.  
Statin use in the study group 
In the study group of 100 patients, 90 had a prescription for a statin. 
Of these, 62 were on 20mg, 27 on 40mg and 1 patient on 80mg of 
simvastatin. Simvastatin was the only statin prescribed. 
Patient group not receiving statins 
The 10 patients who did not receive a statin had the following LDL-C 
values:  
Table 41: LDC-C values of patients not on statins 
 LDL-C <1.8 1.8 ≤ LDL-C < 2.5 LDL-C ≥ 2.5 
Patients numbers n=4 n=4 n=2 
 
4 patients had a LDL-C value below 1.8mmol/l. By applying the 2012 
SEMDSA guidelines all of them qualified for statin therapy except for one. 
This patient had a LDL-C of 0.7 mmol/l, diabetes duration of 5 years and 
no additional risk factors for cardiovascular disease. All the patients with 
LDL-C value >1.8 mmol/l qualified for statin therapy. This means that 9/10 
or 90% of the patients who did not receive a statin qualified for it according 
to the 2012 SEMDSA guidelines. 
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Statin prescribed group 
Ninety patients did receive a statin. It is not possible to fully ascertain if 
patients in this group were receiving statins in error when compared to 
guidelines as access to their initial lipogram before initiation of therapy was 
not available. It is assumed that they would all qualify. 
Table 42: LDL-C values of patients on statins 
Statin dosage Patients LDL-C < 1.8* 1,8 ≤ LDL-C < 2.5* LDL-C ≥ 2.5* 
20mg 62 17 18 27 
40mg 27 4 7 16 
80mg 1 LDL-C not calculated due to high triglyceride level 
  *LDL-C measured in mmol/l 
After applying the SEMDSA lipid guidelines with respect to Type 2 
diabetes patients in the above table only the patients with a LDL-C < 1.8 
mmol/l were at goal. None of the patients in the groups with LDL-C ≥ 1.8 
mmol/l were at goal. This means there was not a single patient who met 
criteria for a less stringent LDL-C goal of < 2.5 mmol/l. If the one patient 
on 80 mg of simvastatin, who is excluded due to a high triglyceride level, is 
left from analysis it means that (21/89) 23.5% of the patients were at goal 
LDL-C level. 
Table 43: LDL-C goal versus statin dosage 
 
 
 
 
Statin prescription and lipid goals conclusion 
Ninety percent of the patients who were not receiving statin therapy 
required it according to the guidelines. 
Statin dosage LDL-C at goal LDL-C not at goal 
20mg 17/62 = 27% 45/62 = 73% 
40mg 4/27 = 15% 23/27 = 85% 
80mg Not calculated due to high TGL value 
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The largest proportion of the group on statins was not controlled at goal: 
73% of the group on 20mg and 85% of the group on 40mg were not at goal. 
In total 23.5% of patients on statins were at goal according to the 2012 
SEMDSA guidelines. 
3.5.3. Laboratory investigation frequency 
3.5.3.1. Urea, creatinine and electrolytes testing frequency 
2012 SEMDSA guidelines 
The 2012 SEMDSA guidelines state that urea, creatinine and electrolytes 
(U&E) should be checked annually for patients with normal renal function. 
It should be checked every 3 months if the eGFR is < 60 ml/min/1.73m
2
 or 
if the albumin creatinine ratio (ACR) is abnormal
 92 
.  
Urea, creatinine and electrolyte testing in the study group 
All of the patients in the study group did have a previous U&E test on the 
laboratory computer system. Thirty one of the patients ie 31% did not have 
a U&E done in the previous year. The mean time between the research 
clinic visit date and the previous U&E test date was 302.8 days. 
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Figure 6: Time difference between research clinic date and previous U&E taken 
Patients with eGFR < 60 ml/min/1.73m
2
 
There were 25 patients with an eGFR < 60 ml/min/1.73m
2
.  
Table 44: Time of previous U&E before clinic date in group with eGFR < 60 ml/min/1.73m2 
Previous 
U&E 
(months) 
 < 3     3-6 6-12  > 12  Total 
Numbers 7 (28%) 7 (28%) 3 (12%) 8 (32%) 25 
 
From this table it is clear that only 7 patients in the group of 25 with eGFR 
< 60 ml/min/1.73m
2
 (28%) met the 2012 SEMDSA guidelines for U&E 
screening frequency. The mean time between previous U&E date and clinic 
visit date for this group was 296.28 days. 
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Figure 7: Time between research clinic date and previous U&E done in patients with GFR < 60 
ml/min/1.73m2 
Conclusion 
The frequency of U&E monitoring in the clinic for this study group does 
not meet the standard put forward by the SEMDSA guidelines. This also 
holds for the patients with renal impairment. 
3.5.3.2. Lipogram testing frequency 
2012 SEMDSA guideline 
The SEMDSA guideline for lipid monitoring recommends annual testing. It 
should be done more often if lipids are high or after treatment has been 
altered.
 86 
 
Lipogram frequency found in this study  
All of the patients in the study did have a lipogram on the laboratory 
computer system. Thirty seven of the 100 patients (37%) did not have a 
lipogram listed for the previous year. 
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The mean time between the clinic study visit date and lipogram date listed 
on the laboratory system was 378.68 days. 
 
Figure 8: Time difference between research clinic date and lipogram date 
Conclusion 
The frequency of lipogram monitoring in the clinic for this study group did 
not meet the standard put forward by the 2012 SEMDSA guidelines. 
3.5.3.3. Screening for chronic kidney disease (CKD) using ACR 
2012 SEMDSA guidelines 
The SEMDSA guidelines suggest screening for CKD with ACR in all Type 
2 diabetes patients on presentation. If this initial value is abnormal it should 
be repeated within 3 months to confirm the diagnosis of CKD. If a 
diagnosis of CKD is confirmed the patient should be monitored with an 
ACR test every 6 months
 92 
.  
ACR screening in the total study population 
Thirty two (32%) of patients in the study population did not have any urine 
protein test registered on the National Health Laboratory System (NHLS). 
 66 
 
Most patients had a urine PCR test registered (n=47). Unfortunately the 
urine PCR test is not sensitive enough to reveal microalbuminuria. Only 21 
(21%) patients were screened for diabetic nephropathy using an ACR test. 
The breakdown of the test frequency of the 68 patients (21 with ACR and 
47 with PCR) who did have urine proteins done are presented in the next 
table: 
Table 45: Time between clinic date and previous urine protein analysis done date 
 Number of 
patients 
Number of tests 
done in the previous 
year 
Mean time in days between research 
date and previous test result 
Patients 
with urine 
ACR 
n=21 7 (33%) 802.66 
Patients 
with urine 
PCR 
n=47 9 (19%) 903.5 
 
 
Figure 9: Time difference between research clinic date and previous urine ACR test date 
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Figure 10: Time difference between research clinic date and previous urine PCR test date 
 
Urine protein screening in the subgroup with eGFR < 60 
ml/min/1.73m
2
 
As noted previously, 25 patients in the study population had an eGFR of 
less than 60 ml/min/1.73m
2
. 
Table 46: Urine protein analysis for the 25 patients with eGFR < 60 ml/min/1.73m2 
 Number of 
patients 
Number of tests 
done in the previous 
year 
Tests done in the last 
6 months 
Patients with 
urine ACR 
n=0 0 (0%) 0 
Patients with 
urine PCR 
n=13 3 (23%) 3 (23%) 
 
2012 SEMDSA guidelines for diagnosis of CKD according to urine 
ACR 
The 2012 SEMDSA guidelines define microalbuminuria in males as a urine 
ACR > 2.0 mg/mmol. In order to diagnose CKD a single abnormal urine 
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ACR with the addition of 1 out of 2 abnormal values is needed, when 
repeating the subsequent tests within 3 months of the initial test
 3,84,86 
. A 
single urine ACR test was used for the following analysis: 
Urine protein screening in males with ACR > 2.0 mg/mmol 
There were 4 males with an ACR > 2.0 mg/mmol. None of them had a 
urine ACR test listed for the 6 months prior to the research clinic date. 
Three out of four (75%) of them had a urine ACR test done in the previous 
year. The mean time between the research clinic date and the previous urine 
ACR test date for this subset was 693.75 days. 
Urine protein screening in females with ACR > 2.8 mg/mmol 
As in the previous section a single urine ACR value was used for the 
following analysis. There were 5 females in the study population with an 
ACR > 2.8 mg/mmol. In this subgroup of patients none of the previous 
urine ACR tests were done in the previous 6 months. Two (40%) of them 
were done in the previous year.  
The mean time between the research clinic date and the previous urine 
ACR test date was 506.8 days. 
Conclusion 
It seems that most of the patients in this study population (47%) were 
screened for proteinuria using the incorrect test (urine PCR).  
The screening frequency does not meet the 2012 SEMDSA guidelines.   
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4. CHAPTER 4 – DISCUSSION 
4.0. Description of the study population 
4.0.1. Smoking 
It was heartening to see that 35% of the patients were ex-smokers. This number 
was higher than the number of smokers in the group (26%) and also higher than the 
number of non-smokers (31%).  
4.0.2. Employment, income and living conditions 
Most of the patients in this cohort were not employed (86%) but this includes a 
large number of retired patients. In the age group < 60 years (n=34), 22 (65%) were 
not employed which is an alarming unemployment rate. The median income per 
person for this study population was R1200 per month with an interquartile range 
of R600 - R1750. There were, therefore, similar incomes across the study 
participants. This poor monthly income might be a major confounder in this study 
as healthy living is expensive, especially from a diet perspective. But it must be 
noted that income on it’s own can’t be used as proxy for diet. Most of the patients 
lived in a house (n=77). The population density average per house was 1.5 persons 
per bedroom. Only 9 patients did not have hot water at home. All of the patients in 
the study had a fridge and toilet facilities. 
4.0.3. Measurements 
The mean BMI (32.5 ± 6.4 kg/m
2
) found in this study is classified as class I obesity 
according to the WHO. The mean waist circumference (106.4  15.0 cm) in the 
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group was markedly increased and significantly more than the target recommended 
by the 2012 SEMDSA guidelines
 86 
.  
 
The females were more obese compared to the males, especially after removing the 
largest male individual who had a waist circumference of 106 cm and a BMI of 
54.90 kg/m
2
 from the male group.  
 
The mean systolic blood pressure of 144.5 mmHg is classified as stage I 
hypertension according to the JNC VII criteria
 85 
. The mean diastolic blood 
pressure of 78.0 mmHg would be classified as acceptable
 85 
. 
4.0.4. Laboratory results 
The mean clinic glucose for the day, 10.4 ± 4.8 mmol/l, was higher than the post 
prandial goal of 5.0-10.0 mmol/l stipulated by the 2012 SEMDSA guidelines for 
the majority of Type 2 diabetic patients
 3 
. 
 
The mean HBA1C for the total group is not close to the 2012 SEMDSA guidelines 
for control and would constitute poor glycaemic control
 3 
. The value of 9.74 % is 
not even close to the less stringent goal of 7.5 % to 8.0 %, the goal recommeded for 
the elderly, hypoglycaemic unaware, poor short-term prognosis, established 
cardiovascular disease or high cardiovascular risk patients
 3 
.  
 
The mean HBA1C was lower in the male group (9.19 ± 1.9 %) when compared to 
the females (9.95 ± 2.27 %). This could be explained by the increased adiposity in 
the female group signified by increased BMI and waist circumference when 
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compared to the males. As mentioned previously, removal from analysis of the 
largest individual in the study group, a male with a waist circumference of 186 cm 
and BMI of 54.90 kg/m
2
, makes the difference in adiposity between the male and 
female group even more pronounced. 
 
The mean total cholesterol, LDL-C and HDL-C are close to the SEMDSA 
guidelines
 86 
. It must be noted that the mean LDL-C value (2.52 mmol/l) was close 
to goal (< 2.50 mmol/l) for patients who meet all of the following criteria: less than 
40 years old or duration of diabetes less than 10 years, no cardiovascular disease, 
no chronic kidney disease and no other cardiovascular risk factors
 86 
. Most of the 
patients in the study population did not fall into this category and would need an 
LDL-C value < 1.8 mmol/l according to the 2012 SEMDSA guidelines
 86 
. The 
mean triglyceride value (2.08 mmol/l) was well above the recommended value of 
1.7 mmol/l recommended by SEMDSA
 86 
. However the laboratory results did not 
specify if the triglyceride test was done on a fasting blood sample which might 
impact the level recorded.  
 
Unfortunately there were only 21 patients with a registered urine 
albumin/creatinine ratio. The mean value for the males (n=6) and females (n=15) 
were in the microalbuminuria range. The microalbuminuria range is 2.0 – 20.0 
mg/mmol for males and 2.8 – 28.0 mg/mmol for females according the 2012 
SEMDSA guidelines
 92 
. Most of the patients with urine protein analysis (n=47) had 
a urine protein/creatinine ratio listed on the National Health Laboratory System 
(NHLS). This is the incorrect test for assessment of proteinuria in diabetes, a urine 
albumin/creatinine ratio test is recommended. 
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4.1. Results of the statistical analysis 
The following section discusses the variables used in this study and their impact on 
glycaemic control. 
4.1.1. Variables found not to have a statistical impact on glycaemic control  
Although a paper published in 2006 cited education level as a predictor of 
glycaemic control this was not supported in our study
 71 
. It must be noted that the 
mean education level in this group was low and that this might be the confounding 
factor. Comparing 2 groups with marked differences in education level might 
reveal a different result.  
 
The duration of diabetic clinic attendance did not reveal a statistical improvement 
in glycaemic control.  
 
The number of co-morbidities suffered by a patient, even after sub-analysis of the 
most prevalent ones, did not predict glycaemic control.  
 
The patient’s opinion about the seriousness of diabetes as a disease did not have 
any bearing on their level of glycaemic control.  Smoking is cited to worsen 
glycaemic control by increasing insulin resistance
 18 
. In this study no association 
could be found between smoking and glycaemic control. None of the smoking 
variables (being a smoker, non-smoker, previous smoker, the pack years smoked or 
duration stopped smoking for previous smokers) had any statistical bearing on 
glycaemic control. 
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In this study, the mean income per person did not show any effect with respect to 
glycaemic control. Although proper nutrition is listed in the literature as a factor 
improving glycaemic control, it is expensive
 78 
. Most of the patients in the study 
had similar income. Comparing this group of patients to a group with substantially 
higher income might have shown an effect on glycaemic control.  
 
The patient’s opinion about his or her own health did not have a statistical impact 
on glycaemic control. It was surprising to find that neither knowledge of ways to 
improve glucose levels or knowledge of things checked in the clinic played any 
role with respect to glycaemic control as diabetes education, which would improve 
these entities, has been shown to improve glycaemic control
 76 
. 
 
The average knowledge of diabetes was very poor. This includes ways to improve 
glucose, things to check in the clinic as well as possible complications. Only 2 
patients (2%) were able to mention 4 things that would improve your glucose 
control. Six patients could not mention anything that would improve their 
glycaemic control. An alarming 22% of patients could not mention a single test or 
procedure done in the clinic to ensure their well-being as a diabetic patient.   
Exercise has been cited as improving glucose control
 68 
. This was not found in this 
study. Exercise frequency reported did not have an impact on glycaemic control. 
This finding could be secondary to self-reporting bias. 
 
Unfortunately this study could not show any benefit related to diabetes education 
even though this is supported in the literature
 76 
. The input from a dietician in the 
previous year also had no effect on glycaemic control.  
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Internet access did not have any impact on glycaemic control. 
 
Knowledge or experience of hypo- and hyperglycaemic symptoms did not 
statistically predict glycaemic control. The literature cites that self-monitoring of 
blood glucose improves control
 79 
. Neither the ownership of a glucose monitor or 
the frequency of glucose testing revealed any benefit with respect to glycaemic 
control. This could be explained by the poor knowledge base found amongst the 
study population. Having a monitor without the knowledge of what to aim for and 
how to get there would be futile. 
 
Glucose measurement value on the research clinic day as well as the value did not 
statistically predict glycaemic control.   
 
The finding that 78% of the patients were able to identify their medication with 
100% accuracy was surprising. Although this finding does not imply compliance it 
at least confirms that the diabetic population included in this study know their 
medication and how to take it. The correct identification of medicine did not, 
however, translate to glycaemic control. 
 
Neck circumference and systolic blood pressure had no statistically significant  
influence on glycaemic control. 
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Neither the total cholesterol, LDL-C, HDL-C, triglyceride nor urea value had any 
statistically significant effect on glycaemic control. The urine PCR value also did 
not emerge as a predictor of glycaemic control.  
4.1.2. Variables with an impact on glycaemic control  
4.1.2.1. Factors associated with improved glycaemic control 
Increase in age, increase in duration of diabetes, increase in eGFR, more 
frequent hypoglycaemic episodes and suffering a diabetic complication, 
specifically a microvascular complication, all seem to be associated with 
better glycaemic control. 
 
In comparing the above list with the current available literature only an 
increase in age is cited
 77 
.  
 
An increase in age and duration of diabetes might both lead to a decrease in 
glomerular filtration rate as the kidney is part of insulin metabolism
 95 
. 
With long standing diabetes the incidence of microvascular complications, 
in this case renal dysfunction, would be increased. This is in contrast to the 
finding in this study that an increase in eGFR was associated with better 
glycaemic control. However it must be stated that the confidence intervals 
for all these variables did cross 1.0, making the results less reliable. 
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  Figure 11: Duration of diabetes versus eGFR in study population 
One could postulate that knowledge of diabetes should increase with 
duration of diabetes culminating in an improvement of control. In this study  
longer duration of diabetes revealed a poorer knowledge of diabetes as can 
be seen in the following figure: 
 
  Figure 12: Duration of diabetes versus knowledge to improve control in study population 
 
More frequent hypoglycaemic episodes might indicate patients actually 
attempting control and thus achieving better values. Analysis of this 
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variable was done by contrasting these patients with patients who have 
never experienced any symptoms of hypoglycaemia. 
 
The finding that experience of a diabetic complication improves control 
might show that real experience speaks louder than words. 
4.1.2.2. Factors associated with poorer glycaemic control 
An increase in diastolic blood pressure, a higher dose of daily aspirin, a 
higher dose of simvastatin and an increased body mass index were all 
associated with worse glycaemic control.  
 
None of the above, except for body mass index has been cited in the 
literature reviewed for this research
 11 
. 
 
It was interesting to find that an increased diastolic blood pressure was a 
predictor of poorer glycaemic control. This might be a surrogate marker for 
worsening autonomic dysfunction with impact on glycaemic control. 
 
It must be noted that the confidence interval found with the increased 
aspirin dose variable did not cross 1.0. This makes this finding highly 
significant.  Although compliance was not measured, most patients 
identified their medication accurately. Seventy-eight percent made no error 
with medication identification, which would support excellent compliance. 
Perhaps aspirin in itself has pharmacodynamic properties with an impact on 
glycaemic control. This could be a topic for further research. 
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A number of articles have reported an increased risk of developing diabetes 
with the use of statins
 20,22,96 
. The effect of statins on glycaemic control in 
known diabetes is less well known. Although this was an observational 
study and confidence intervals were wide and crossing 1.0, the statin 
dosage analysis result revealed that higher statin dosages was associated 
with poorer glycaemic control. 
4.2. Correlations between HBA1C and blood pressure, lipids, waist circumference and 
body mass index 
Most of the correlations found in this study were expected. Positive correlations between 
total cholesterol, LDL-C and HDL-C, would be expected, as would a positive correlation 
between systolic and diastolic blood pressure and between body mass index and waist 
circumference. 
 
It was interesting to note that diastolic blood pressure did not only have a positive 
correlation with the systolic blood pressure but also with the HBA1C and triglyceride 
levels. The HBA1C correlation might be related to the microvascular complication of 
autonomic dysfunction as diastolic blood pressure is related to the autonomic function of 
the vasculature. The other possibility is that glucose might have a direct effect on vascular 
tone as well as the production of triglycerides. 
 
Body mass index and waist circumference did not have a significant correlation with 
HBA1C in this study (p = 0.8152 and 0.7639 respectively). This was a surprising finding. 
Obesity has been cited as a risk factor for developing diabetes and weight loss has been 
cited to improve glycaemic control
 11 
.  
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4.3. Comparison of diabetic clinic treatment targets, treatment prescribed and 
laboratory investigation against the 2012 SEMDSA guidelines 
Very few patients met the targets for waist circumference and blood pressure in this study 
when compared to the 2012 SEMDSA guidelines. Only 6 males (21%) and no females 
had a waist circumference at target.  
 
Blood pressure analysis was done on a single clinic blood pressure measurement. 
Previously it was mentioned that there might be possible confounders to the blood 
pressure measurement (Section 3.5.1.2). If the blood pressure reading can be trusted only 
15 patients (15%) were at goal blood pressure according to the 2012 SEMDSA 
guidelines. A worrying 86% of the patients with blood pressure below the guideline blood 
pressure were receiving hypertensive treatment. Most of the patients with a blood 
pressure higher than recommended by the guideline were receiving treatment. Only 5/63 
(8%) of patients in this group did not receive anti-hypertensive treatment. 
 
In the group of patients without a prescription for aspirin (n=7), 6 (86%) did qualify 
according to the 2012 SEMDSA guidelines. 
 
After evaluation of the patients with aspirin prescriptions it was clear that aspirin therapy 
was over prescribed in the younger male and female population. None of the males ≤ 50 
years of age qualified for aspirin therapy but were all receiving it. In the female group  ≤ 
60 years of age, 25/27 also received aspirin incorrectly according to the 2012 SEMDSA 
guidelines. The numbers were a lot better in the older patient groups. In the group of 
males older than 50 only 5% received aspirin in error and in the female group 0%.  
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In the group of 10 patients who did not have a prescription for a statin, 9 were eligible 
according to the 2012 SEMDSA guidelines. 
 
Using the latest lipogram result only 23.5% of the patients on statin therapy were at LDL-
C goal according to the 2012 SEMDSA guidelines. 
 
The mean time between the research clinic visit date and the previous urea, creatinine and 
electrolytes measurements recorded on the system was 302.8 days. Thirty one percent of 
patients did not have a urea, creatinine and electrolyte test performed in the previous year. 
In the subgroup of patients with renal impairment (n=25), only 7/25 (28%) had a urea, 
creatinine and electrolyte test listed in the previous 3 months. The frequency of U&E 
monitoring could be markedly improved in the clinic when compared to the 2012 
SEMDSA guidelines. 
 
The mean time between the research clinic date visit and the previous lipogram on the 
NHLS computer system was 378.68 days. There was no lipogram recorded for 37% of the 
patients in the previous year. The frequency of lipogram monitoring fell short of the 2012 
SEMDSA guidelines and could be improved. 
 
Although the mean time period of clinic attendance for the study population was 10.93 
years, there were 32 patients (32%) without any urine protein recorded in the NHLS 
computer system. For most patients in the study group who did have a urine protein test 
recorded the wrong investigation in the form of a urine PCR test was requested. A urine 
PCR test was requested for 47% of the patients. In the urine PCR test group only 19% of 
tests were conducted in the previous year. 
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Only 21 patients (21%) were screened for albuminuria using a urine ACR test. In this 
group only 33% of tests were done in the previous year. 
 
In the subgroup of patients with an eGFR < than 60 ml/min/1.73m
2
 none had a listed 
urine ACR test and 13 had a listed urine PCR test. Of the 13 who had urine PCR tests 
listed only 3 (23%) were done in the previous year. 
 
In the group of male patients with ACR > 2.0 mg/mmol none of them had a previous 
ACR done in the 6 months prior to the research clinic date. 
 
In the group of female patients with a urine ACR > 2.8 mg/mmol there were also no urine 
ACR values for the previous 6 months. 
 
Screening for and monitoring of chronic kidney disease was significantly below standard 
when compared to the 2012 SEMDSA guidelines. 
4.4. Limitations of the study 
Some variables cited in the literature were not investigated in this study. 
 
Diet has been cited to have an impact on glycaemic control but was left from data 
acquisition as proper investigation of this entity would be very time consuming
 68 
.  
A recent study published this year found that diabetes was an independent risk factor for 
dementia
 97 
. The cohort I examined had significant exposure to diabetes (mean duration 
of 15.8 years) and was elderly (mean age of 62.8 years). Although I did not screen for 
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underlying dementia, its presence would have a significant impact on glycaemic control 
and might have confounded some of the variables. 
 
Adherence to lifestyle modification and medication play a role in glycaemic control. 
Although medication identification was evaluated, neither compliance with medication or 
lifestyle adherence was assessed which limits this study. 
 
Using a larger sample size would improve confidence intervals and p values in this study. 
 
It must be kept in mind that the likelihood of finding a chance statistically significant 
effect exists given the multiple comparisons and the use of non-validated questionnaires 
and scores. 
4.5. Conclusion 
It was found to be extremely challenging to narrow down predictors of glycaemic control 
as a vast number of variables could play a role. To improve statistical significance large 
patient numbers would be needed to show differences. 
 
In this study a selection of variables were chosen and investigated.  
The study population was elderly, had a long duration of diabetes, poor education level 
and also had very poor socio-economic status. 
 
The knowledge of diabetes management and complications was extremely poor but 
surprisingly the patients were very knowledgeable with respect to their medication. 
 
 83 
 
Increase in age, duration of diabetes, increase in eGFR , diabetic complications suffered 
and more frequent hypoglycaemic episodes were all found to be associated with better 
glycaemic control. 
 
An increased diastolic blood pressure, aspirin dose, statin dose and body mass index all 
predicted worse glycaemic control. 
 
It was interesting to find that smoking, education level, monthly income and knowledge 
of diabetes did not predict glycaemic control. As previously stated, the education level 
and income of the group was similar. Without adequate differences it would be difficult 
to show statistical effect. 
 
This was an observational study with limited power. Further study would be needed with 
respect to aspirin and statin dosage and their relationship with glycaemic control.   
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UNIVERSITY OF WITWATERSRAND 
 
CONSENT TO ACT AS A SUBJECT IN RESEARCH 
 
I,____________________________________________ being 18 years or older consent to 
participating in a research project entitled: 
PREDICTORS OF GLYCAEMIC CONTROL IN TYPE 2 DIABETES PATIENTS AT 
HELEN JOSEPH HOSPITAL DIABETIC CLINIC 
The procedures/questionnaires have been explained to me and I understand and appreciate 
their purpose and the extent of my involvement. I have read and understand the attached 
information leaflet. 
I understand that the procedures form part of a research project, and may not provide any 
direct benefit to me. 
I understand that all experimental procedures have been sanctioned by the Committee for 
Research on Human Subjects, University of the Witwatersrand, Johannesburg. 
I understand that my participation is voluntary, and that I am free to withdraw from the project 
at any time without prejudice. 
 
 
_________________________                                 __________________________ 
Participant name and signature                                 Date 
 
 
_________________________                                 __________________________ 
Investigator name and signature                               Date 
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8. APPENDIX C: Patient information leaflet 
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INFORMATION DOCUMENT  
 
Study title: Predictors of Glycaemic Control in Type 2 Diabetes Patients at Helen Joseph 
Hospital Diabetic Clinic 
 
Good day 
 
I am Dr. Daniel Roux and I am doing a research project as part of a degree. Research is just 
the process to learn the answer to a question. In this study I am trying to find things that 
determine good control of blood glucose.  
 
I am inviting you to take part in this research study.  
 
Your involvement would consist of a short interview with a few questions, a few 
measurements (I will take blood pressure, weight, height, measure your waist and neck), 
record your current medication and also have a look at your latest blood results to see how 
well your glucose is controlled.  
 
There is absolutely no risk to you by being involved in the study.  
 
You might not see direct benefits of the study but we might learn things from this study that 
might improve your care later on. 
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Participation is voluntary. Refusal to participate will involve no penalty or loss of benefits to 
which you would be entitled. You may discontinue at any time without penalty or loss of 
benefits. You do not have to answer any of the questions if you do not want to. 
 
Efforts will be made to keep personal information confidential.  Absolute confidentiality 
cannot be guaranteed even though none of your personal identification details will be 
recorded. Personal information may be disclosed if required by law. 
If results are published it may lead to cohort identification. 
 
You are welcome to contact Dr. Daniel Roux at Helen Joseph Hospital if you have any 
questions or concerns. Phone 011 489 1011 and ask for 50615.  
 
You can also contact the REC administrator and chair – for reporting of complaints or 
problems at 011 717 1234 
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9. APPENDIX D: Patient data collection sheet 
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10. APPENDIX E:  Pearson correlation coefficient table 
Pearson correlation coefficients 
  HBA1C Systolic 
blood 
pressure 
Diastolic 
blood 
pressure 
Total 
cholesterol 
Triglycerides HDL-C LDL-C Body 
mass 
index 
Waist 
circumference 
HBA1C r 1.0 0.02139 0.29981 0.09541 0.13094 -0.05685 0.09329 0.02367 -0.03041 
 p  0.8327 0.0024 0.3450 0.1941 0.5743 0.3660 0.8152 0.7639 
 n 100 100 100 100 100 100 96 100 100 
Systolic blood 
pressure 
r 0.02139 1.0 0.55712 0.18590 0.20834 -0.14335 0.12233 0.15645 0.15875 
 p 0.8327  < 0.0001 0.0640 0.0375 0.1548 0.2351 0.1201 0.1147 
 n 100 100 100 100 100 100 96 100 100 
Diastolic blood 
pressure 
r 0.29981 0.55712 1.0 0.19193 0.35611 -0.15526 0.09484 0.02298 0.06248 
 p 0.0024 < 0.0001  0.0557 0.0003 0.1230 0.3580 0.3580 0.5369 
 n 100 100 100 100 100 100 96 100 100 
Total cholesterol r 0.09541 0.18590 0.19193 1.0 0.48292 0.37798 0.86673 0.02097 -0.03117 
 p 0.3450 0.0640 0.0557  < 0.0001 0.0001 < 0.0001 0.8359 0.7582 
 n 100 100  100 100 100 96 100 100 
Triglycerides r 0.13094 0.20834 0.35611 0.48292 1.0 -0.08284 -0.08284 0.04339 0.10881 
 p 0.1941 0.0375 0.0003 < 0.0001  0.1432 0.4223 0.6682 0.2812 
 n 100 100 100 100 100 100 96 100 100 
HDL-C r -0.05685 -0.14335 -0.15526 0.37798 -0.14746 1.0 0.24368 -0.03362 -0.18846 
 p 0.5743 0.1548 0.1230 0.0001 0.1432  0.0167 0.7398 0.0604 
 n 100 100 100 100 100 100 96 100 100 
LDL-C r 0.09329 0.12233 0.09484 0.86673 -0.08284 0.24368 1.0 0.04786 -0.04197 
 p 0.3660 0.2351 0.3580 < 0.0001 0.4223 0.0167  0.6433 0.6847 
 n 96 96 96 96 96 96 96 96 96 
Body mass index r 0.02367 0.15645 0.02298 0.02097 0.04339 -0.03362 0.04786 1.0 0.82496 
 p 0.8152 0.1201 0.3580 0.8359 0.6682 0.7398 0.6433  < 0.0001 
 n 100 100 100 100 100 100 96 100 100 
Waist 
circumference 
r -0.03041 0.15875 0.06248 -0.03117 0.10881 -0.18846 -0.04197 0.82496 1.0 
 p 0.7639 0.1147 0.5369 0.7582 0.2812 0.0604 0.6847 < 0.0001  
 n 100 100 100 100 100 100 96 100 100 
 
